US20050267323A1 - Apparatus and methods for treating stroke and controlling cerebral flow characteristics - Google Patents

Apparatus and methods for treating stroke and controlling cerebral flow characteristics Download PDF

Info

Publication number
US20050267323A1
US20050267323A1 US11/146,636 US14663605A US2005267323A1 US 20050267323 A1 US20050267323 A1 US 20050267323A1 US 14663605 A US14663605 A US 14663605A US 2005267323 A1 US2005267323 A1 US 2005267323A1
Authority
US
United States
Prior art keywords
catheter
flow
lumen
intake port
wire
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11/146,636
Inventor
Gerald Dorros
Juan Parodi
Claudio Schonholz
Michael Hogendijk
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
WL Gore and Associates Inc
Original Assignee
Gerald Dorros
Parodi Juan C
Schonholz Claudio J
Michael Hogendijk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gerald Dorros, Parodi Juan C, Schonholz Claudio J, Michael Hogendijk filed Critical Gerald Dorros
Priority to US11/146,636 priority Critical patent/US20050267323A1/en
Publication of US20050267323A1 publication Critical patent/US20050267323A1/en
Assigned to W. L. GORE & ASSOCIATES, INC. reassignment W. L. GORE & ASSOCIATES, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: GORE ENTERPRISE HOLDINGS, INC.
Abandoned legal-status Critical Current

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/32Surgical cutting instruments
    • A61B17/3205Excision instruments
    • A61B17/3207Atherectomy devices working by cutting or abrading; Similar devices specially adapted for non-vascular obstructions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/12Surgical instruments, devices or methods, e.g. tourniquets for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels, umbilical cord
    • A61B17/12022Occluding by internal devices, e.g. balloons or releasable wires
    • A61B17/12027Type of occlusion
    • A61B17/1204Type of occlusion temporary occlusion
    • A61B17/12045Type of occlusion temporary occlusion double occlusion, e.g. during anastomosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/12Surgical instruments, devices or methods, e.g. tourniquets for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels, umbilical cord
    • A61B17/12022Occluding by internal devices, e.g. balloons or releasable wires
    • A61B17/12099Occluding by internal devices, e.g. balloons or releasable wires characterised by the location of the occluder
    • A61B17/12109Occluding by internal devices, e.g. balloons or releasable wires characterised by the location of the occluder in a blood vessel
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/12Surgical instruments, devices or methods, e.g. tourniquets for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels, umbilical cord
    • A61B17/12022Occluding by internal devices, e.g. balloons or releasable wires
    • A61B17/12131Occluding by internal devices, e.g. balloons or releasable wires characterised by the type of occluding device
    • A61B17/12136Balloons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/12Surgical instruments, devices or methods, e.g. tourniquets for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels, umbilical cord
    • A61B17/12022Occluding by internal devices, e.g. balloons or releasable wires
    • A61B17/12131Occluding by internal devices, e.g. balloons or releasable wires characterised by the type of occluding device
    • A61B17/12168Occluding by internal devices, e.g. balloons or releasable wires characterised by the type of occluding device having a mesh structure
    • A61B17/12172Occluding by internal devices, e.g. balloons or releasable wires characterised by the type of occluding device having a mesh structure having a pre-set deployed three-dimensional shape
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/22Implements for squeezing-off ulcers or the like on the inside of inner organs of the body; Implements for scraping-out cavities of body organs, e.g. bones; Calculus removers; Calculus smashing apparatus; Apparatus for removing obstructions in blood vessels, not otherwise provided for
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/22Implements for squeezing-off ulcers or the like on the inside of inner organs of the body; Implements for scraping-out cavities of body organs, e.g. bones; Calculus removers; Calculus smashing apparatus; Apparatus for removing obstructions in blood vessels, not otherwise provided for
    • A61B17/221Gripping devices in the form of loops or baskets for gripping calculi or similar types of obstructions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/12Surgical instruments, devices or methods, e.g. tourniquets for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels, umbilical cord
    • A61B17/12022Occluding by internal devices, e.g. balloons or releasable wires
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/22Implements for squeezing-off ulcers or the like on the inside of inner organs of the body; Implements for scraping-out cavities of body organs, e.g. bones; Calculus removers; Calculus smashing apparatus; Apparatus for removing obstructions in blood vessels, not otherwise provided for
    • A61B17/22031Gripping instruments, e.g. forceps, for removing or smashing calculi
    • A61B2017/22034Gripping instruments, e.g. forceps, for removing or smashing calculi for gripping the obstruction or the tissue part from inside
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/34Trocars; Puncturing needles
    • A61B17/3417Details of tips or shafts, e.g. grooves, expandable, bendable; Multiple coaxial sliding cannulas, e.g. for dilating
    • A61B17/3421Cannulas
    • A61B2017/3435Cannulas using everted sleeves
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M25/00Catheters; Hollow probes
    • A61M25/01Introducing, guiding, advancing, emplacing or holding catheters
    • A61M25/09Guide wires
    • A61M2025/09008Guide wires having a balloon
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M25/00Catheters; Hollow probes
    • A61M25/01Introducing, guiding, advancing, emplacing or holding catheters
    • A61M25/09Guide wires
    • A61M2025/09058Basic structures of guide wires
    • A61M2025/09083Basic structures of guide wires having a coil around a core
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M25/00Catheters; Hollow probes
    • A61M25/01Introducing, guiding, advancing, emplacing or holding catheters
    • A61M25/09Guide wires
    • A61M2025/09166Guide wires having radio-opaque features
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M25/00Catheters; Hollow probes
    • A61M25/10Balloon catheters
    • A61M2025/1043Balloon catheters with special features or adapted for special applications
    • A61M2025/1052Balloon catheters with special features or adapted for special applications for temporarily occluding a vessel for isolating a sector
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M25/00Catheters; Hollow probes
    • A61M25/10Balloon catheters
    • A61M25/1002Balloon catheters characterised by balloon shape

Definitions

  • the present invention relates to improved apparatus and methods for treatment of stroke. More specifically, the apparatus and methods of the present invention are directed to treating stroke by controlling cerebral blood flow and removing thrombi and/or emboli.
  • Cerebral occlusions that lead to stroke require swift and effective therapy to reduce morbidity and mortality rates associated with the disease.
  • Many current technologies for treating stroke are inadequate because emboli generated during the procedure may travel downstream from the original occlusion and cause ischemia.
  • a CT scan or MRI may be used to diagnose the cerebral occlusion, which commonly occurs in the middle cerebral arteries.
  • Many current technologies position a catheter proximal to the occlusion, then deliver clot dissolving drugs to treat the lesion.
  • a drawback associated with such technology is that delivering drugs may require a period of up to six hours to adequately treat the occlusion.
  • Another drawback associated with lytic agents i.e., clot dissolving agents
  • emboli When removing thrombus using mechanical embolectomy devices, it is beneficial to engage the thrombus and remove it as cleanly as possible, to reduce the amount of emboli that are liberated. However, in the event that emboli are generated during mechanical disruption of the thrombus, it is imperative that they be subsequently removed from the vasculature.
  • U.S. Pat. No. 6,161,547 to Barbut (Barbut '547) describes a technique for enhancing flow in the cerebral vasculature in treating patients with acute stroke or other cerebrovascular disease.
  • the technique involves: (1) positioning a first tubular member in a vascular location suitable for receiving antegrade blood flow; (2) positioning a second tubular member in a contralateral artery of the occlusion (e.g., for an occlusion located in the left common carotid artery the second tubular member is placed in the right common carotid artery); and coupling the first tubular member to the second tubular member using a pump and filter.
  • the first tubular member receives antegrade blood flow and channels the blood to the pump and filter, where the blood then is reperfused via the second tubular member into the contralateral artery, thus increasing blood flow to the opposing hemisphere of the brain.
  • the first and second tubular members may include balloons disposed adjacent to their distal ends.
  • the Barbut '547 patent further discloses that inflating the balloon of the second tubular member may assist in controlling the flow to the contralateral artery or provide more efficient administration of pharmacotherapy to the cerebral tissues.
  • the contralateral artery may be starved of sufficient flow, since the only other flow in that artery is that aspirated through the first tubular member.
  • the balloon of the second tubular member is not inflated, no flow control is possible.
  • a method for removing cerebral occlusions is described in U.S. Pat. No. 6,165,199 to Barbut (Barbut '199).
  • This patent describes a catheter having an aspiration port at its distal end that communicates with a vacuum at its proximal end.
  • a perfusion port disposed in a lateral surface of the catheter may be used to enhance antegrade flow in collateral arteries.
  • the aspiration port is positioned proximal to an occlusion to provide a direct suction effect on the occlusion.
  • the perfused flow in collateral arteries is intended to augment retrograde flow distal to the occlusion, such that the occlusion is dislodged via the pressure and directed toward the aspiration port.
  • a chopping mechanism e.g., an abrasive grinding surface or a rotatable blade, coupled to the aspiration port recognizes when the aspiration port is clogged. The chopping mechanism then engages to break up the occlusion and permit it to enter the aspiration port in smaller pieces.
  • the device described in the Barbut '199 patent has several disadvantages.
  • a chopping mechanism is required to prevent the entire mass from clogging the aspiration port.
  • the use of a chopping mechanism may generate such a large quantity of emboli that it may be difficult to retrieve all of the emboli.
  • emboli generated by the action of the chopping mechanism may accumulate alongside the catheter, between the aspiration port and the distal balloon. Once this occurs, it is unclear how the emboli will be removed.
  • Yet another drawback of the device described in the Barbut '199 patent is that high-pressure perfusion in collateral arteries may not augment retrograde flow distal to the occlusion as hypothesized.
  • the patent indicates that high-pressure perfusion in collateral arteries via side ports in the catheter may be sufficient to cause an increase in pressure distal to the occlusion.
  • Antegrade blood flow from the heart in unaffected arteries, e.g., other vertebral and/or carotid arteries may make it difficult for the pressure differential induced in the contralateral arteries to be communicated back to the occluded artery in a retrograde fashion.
  • U.S. Pat. No. 5,794,629 to Frazee describes a method that comprises at least partially occluding the first and second transverse venous sinuses and introducing a flow of the patient's arterial blood to a location distal to the partial venous occlusions.
  • the-infusion of arterial blood into the venous sinuses provides a retrograde venous flow that traverses the capillary bed to oxygenate the ischemic tissues and at least partially resolve ischemic brain symptoms.
  • U.S. Pat. No. 5,895,398 to Wensel et al. describes a shape-memory coil affixed to an insertion mandrel. The coil is contracted to a reduced profile state within the lumen of a delivery catheter, and the catheter is used to cross a clot. Once the coil is disposed distal to the clot, the coil id deployed. The coil then is retracted proximally to engage and remove the clot.
  • a primary drawback associated with the Wensel device is that the deployed coil contacts the intima of the vessel, and may damage to the vessel wall when the coil is retracted to snare the occlusion. Additionally, the configuration of the coil is such that the device may not be easily retrieved once it has been deployed. For example, once the catheter has been withdrawn and the coil deployed distal to the occlusion, it will be difficult or impossible to exchange the coil for another of different dimensions.
  • It still a further object of the present invention to provide apparatus and methods for selectively providing retrograde and/or antegrade flow to desired regions in the cerebral vasculature to effectively remove emboli.
  • a stroke treatment system comprising an emboli removal catheter and one or more flow control devices suitable for manipulating blood flow in the cerebral vasculature.
  • the stroke treatment system may facilitate the introduction and subsequent removal of clot lysing agents, or further comprise a thrombectomy element.
  • the emboli removal catheter is transluminally inserted and disposed in the common carotid artery CCA, and comprises a flexible catheter having an occlusive member disposed on its distal end.
  • the occlusive member is configured to be deployed to anchor the catheter and occlude antegrade flow in the CCA.
  • a separate occlusive element is configured to pass through a lumen of the emboli removal catheter, and is deployed in the external carotid artery ECA to occlude flow through that vessel.
  • One or more flow control devices each having a rapidly deployable occlusive member, then are positioned at selected locations, e.g., in the subclavian arteries, and may be deployed to isolate or redistribute flow through the cerebral vasculature.
  • the flow control devices occlude blood flow in the vertebral and carotid arteries in the hemisphere in which the occlusion is not located. This temporarily influences flow in the opposing hemisphere.
  • the flow control devices are provided in sufficient number that, when deployed, the flow control devices substantially influence the flow dynamic of mid-cerebral artery.
  • a lysing agent may be introduced into the vessel through a lumen of the emboli removal catheter.
  • the occlusive members on one or more of the flow control devices may be collapsed to cause retrograde flow through the cerebral vasculature sufficient to flush the lysing agent and any emboli or debris from the vasculature into the emboli removal catheter.
  • the stroke treatment system and flow control devices may then be withdrawn from the patient's vasculature.
  • a thrombectomy element may be advanced transluminally via the ICA to a position just proximal of a cerebral occlusion, e.g., in the middle cerebral artery, after placement (but prior to deployment) of the flow control devices.
  • the flow control devices then are deployed to selectively and temporarily redistribute or suspend flow in the cerebral vasculature.
  • the thrombectomy element preferably is advanced to the site of the cerebral occlusion through a lumen of the emboli removal catheter.
  • the thrombectomy element With flow controlled throughout the Circle of Willis and therefore the communicating mid-cerebral artery, the thrombectomy element then is engaged with the lesion. Actuation of the thrombectomy element preferably causes mechanical disruption of the emboli or thrombus, after which the element is retracted into the emboli removal catheter. By selectively de-actuating one or more of the flow control devices, retrograde or redistributed flow may be generated in the vasculature that cases emboli liberated during actuation of the thrombectomy element to be directed into the emboli removal catheter. The flow control devices then are withdrawn to reestablish antegrade blood flow.
  • a second emboli removal catheter may be disposed in a vertebral artery in lieu of one of the flow control devices.
  • the lumen of the second emboli removal catheter may be perfused with blood or saline under pressure to induce retrograde flow elsewhere in the cerebral vasculature, such as in the carotid or vertebral arteries.
  • chilled blood and/or drug agents may be delivered via the second catheter to induce mild hypothermia and/or altered pressure gradients at selected cerebral locations.
  • the second emboli removal catheter may be used to enhance flow manipulation in the Circle of Willis and communicating vessels to facilitate removal of emboli via either retrograde or antegrade flow either independently or, or simultaneously with, use of the first emboli removal catheter.
  • FIG. 1 provides a schematic overview of the portion of the vasculature in which the apparatus and methods of the present invention are intended for use;
  • FIG. 2 provides an overview of the apparatus of the present invention deployed in a patient's vasculature
  • FIGS. 3A-3D are, respectively, a schematic view, and detailed side and sectional views of the distal end of an emboli removal catheter of the present invention.
  • FIGS. 4A-4E provide detailed views of the proximal and alternative distal ends of the flow control devices of the present invention contracted and expanded: states;
  • FIGS. 5A-5B are views of alternative embodiments of low profile occlusive elements for occluding flow in the external carotid arteries;
  • FIGS. 6A-6F depict thrombectomy wires having shape memory properties in contracted and deployed states
  • FIGS. 7A-7E illustrate alternative configurations for the thrombectomy wire of FIGS. 6 ;
  • FIGS. 8A-8D illustrate thrombectomy wires configured to engage the fibrin strands of a thrombus
  • FIGS. 9A-9C describe an alternative thrombectomy device configured to engage the fibrin strands of a thrombus
  • FIGS. 10A-10E illustrate method steps for removing an occlusion using the apparatus of FIGS. 9 ;
  • FIG. 11 describes a telescoping catheter configured to be advanced through the main catheter
  • FIGS. 12A-12D describe a telescoping catheter having an expandable distal section configured to be advanced through the main catheter;
  • FIGS. 13A-13H illustrate method steps for controlling cerebral blood flow and removing thrombi and/or emboli in accordance with the present invention
  • FIGS. 14A-14B describe a catheter having an intake port configured to provide for retrograde and/or antegrade flow in either of the carotid or vertebral arteries;
  • FIG. 15 illustrates a proximal assembly suitable for controlling retrograde and antegrade flow in the carotid and vertebral catheters of FIG. 14 ; and FIGS. 16A-16B provide examples of manipulating cerebral flow using a combination of carotid and vertebral catheters, each having antegrade and retrograde flow potential.
  • FIG. 1 a schematic of the pertinent vasculature relating to the present invention is provided.
  • Many cerebral obstructions that lead to stroke reside in the middle cerebral arteries MCA.
  • To treat obstructions in the MCA one approach involves percutaneously and transluminally advancing a therapeutic device to the site of the obstruction via the internal carotid artery ICA.
  • Treating occlusions in the MCA may generate emboli upon removal of the occlusion. Under normal blood flow conditions, such emboli may travel downstream from the original occlusion and cause ischemia. Accordingly, it is advantageous to manipulate blood flow characteristics in the cerebral vasculature to ensure that emboli generated in the MCA are effectively removed.
  • the present invention manipulates cerebral blood flow by inhibiting flow from the heart into any of the vertebral arteries VA and common carotid arteries CCA. This may be achieved by disposing flow control devices in the subclavian arteries SA and/or brachiocephalic trunk BT, to temporarily inhibit flow from the aortic arch AA into any of the vertebral arteries VA and common carotid arteries CCA. This interruption of antegrade flow may advantageously alter flow in the Circle of Willis, as described hereinbelow.
  • FIG. 2 provides an overview of the components of the system of the present invention, each of which are described in greater detail hereinbelow.
  • Flow control devices 8 having occlusive elements 6 are configured to be introduced into the patient's vasculature, e.g., via the radial or brachial arteries. When so positioned, occlusive elements 6 preferably are positioned in the patient's left subclavian artery SA and brachiocephalic trunk BT, as shown. Occlusive elements 6 may have any of a number of designs, with low profile mechanically self-expanding designs being preferred.
  • Emboli removal catheter 2 includes distal occlusive element 4 , and is configured to be percutaneously advanced in retrograde fashion through the descending aorta.
  • Occlusive element 4 preferably comprises a pear-shaped or funnel-shaped balloon as described in copending and commonly assigned U.S. patent application Ser. No. 09/418,727, which is incorporated herein by reference.
  • Occlusive element 4 preferably is positioned proximal to the carotid bifurcation, and then deployed to induce retrograde flow in the ICA by use of a venous return catheter (not shown) that communicates with the proximal end of catheter 2 .
  • Balloon 10 also described in the foregoing application, is deployed in the ECA to ensure that retrograde flow from the ICA is not carried in an antegrade fashion into the ECA.
  • Flow control devices 8 and emboli removal catheter 2 are used to suspend antegrade flow in the cerebral arteries and to selectively suspend or redistribute flow in the cerebral vasculature. Once so-deployed, a lysing agent may be introduced to dissolve the clot, followed by selectively contracting one or more of the flow control devices to induce retrograde flow through emboli removal catheter 2 .
  • thrombectomy wire 12 may be introduced into the vessel containing the lesion.
  • Flow control devices 8 then may be deployed, as shown in FIG. 2 , to prevent flow from the aortic arch AA into the right common carotid artery RCCA and the right and left vertebral arteries VA.
  • Such selective manipulation of flow into the carotid and/or vertebral arteries alters flow characteristics in the cerebral vasculature, and permits retrograde flow through to be induced to flush emboli and debris into the lumen of catheter 2 for removal.
  • thrombectomy wire 12 comprises knot 14 that is deployed distal to the thrombus T.
  • Thrombectomy wire 12 and thrombus T then are retracted proximally into the lumen of emboli removal catheter 2 , and any embolic fragments generated during this procedure are directed into catheter 2 by inducing localized retrograde flow.
  • flow control devices 8 are contracted to reestablish flow to the cerebral vasculature.
  • Apparatus 40 constructed in accordance with the principles of the present invention is described.
  • Apparatus 40 comprises emboli removal catheter 41 , wire 45 , venous return line 52 , tubing 49 and optional blood filter 50 .
  • Catheter 41 includes distal occlusive element 42 , hemostatic ports 43 a and 43 b , e.g., Touhy-Borst connectors, inflation port 44 , and blood outlet port 48 .
  • Wire 45 includes balloon 46 that is inflated via inflation port 47 .
  • Tubing 49 couples blood outlet port 48 to filter 50 and blood inlet port 51 of venous return line 52 .
  • Wire 45 preferably comprises a small diameter flexible shaft having an inflation lumen that couples inflatable balloon 46 to inflation port 47 .
  • Wire 45 and balloon 46 are configured to pass through hemostatic ports 43 a and 43 b and the aspiration lumen of catheter 41 (see FIGS. 3C and 3D ), so that balloon 46 may be disposed in a communicating artery, e.g., the external carotid artery.
  • Ports 43 a and 43 b and the aspiration lumen of catheter 41 are sized to permit additional interventional devices, such as thrombectomy wires, to be advanced through the aspiration lumen when wire 45 is deployed.
  • Venous return line 52 includes hemostatic port 53 , blood inlet port 51 and a lumen that communicates with ports 53 and 51 and tip 54 .
  • Venous return line 52 may be constructed in a manner per se known for venous introducer catheters.
  • Tubing 49 may comprise a suitable length of a biocompatible material, such as silicone. Alternatively, tubing 49 may be omitted and blood outlet port 48 of catheter 41 and blood inlet port 51 of venous return line 52 may be lengthened to engage either end of filter 50 or each other.
  • distal occlusive element 42 comprises expandable funnel-shaped balloon 55 .
  • balloon 55 comprises a compliant material, such as polyurethane, latex or polyisoprene which has variable thickness along its length to provide a funnel shape when inflated.
  • Balloon 55 is affixed to distal end 56 of catheter 41 in an inverted fashion, for example, by gluing or a melt-bond, so that opening 57 in balloon 55 leads into aspiration lumen 58 of catheter 41 .
  • Balloon 55 preferably is wrapped and heat treated during manufacture so that distal portion 59 of the balloon extends beyond the distal end of catheter 41 and provides an atraumatic tip or bumper for the catheter.
  • catheter 41 preferably comprises inner layer 60 of low-friction material, such as polytetrafluoroethylene (“PTFE”), covered with a layer of flat stainless steel wire braid 61 and polymer cover 62 (e.g., polyurethane, polyethylene, or PEBAX).
  • Inflation lumen 63 is disposed within polymer cover 62 and couples inflation port 44 to balloon 55 .
  • the flow control devices may comprise either an inflatable balloon or a mechanically deployable mechanism.
  • a preferred embodiment of the proximal end for a mechanically deployable mechanism comprises controller 70 , delivery port 78 , e.g., for delivering cardioplegic agents, deployment knob 72 that is configured to slide within slot 74 , and guidewire lumen 76 , which may comprise a self-sealing valve.
  • Body 73 houses a plurality of lumens, e.g., a mechanical deployment lumen, a therapeutic drug delivery lumen, and a guidewire lumen.
  • port 78 may serve as an inflation/aspiration port while deployment knob 72 and slot 74 are omitted.
  • FIGS. 4B-4C illustrate the distal end of the flow control device having inflatable balloon 82 in contracted and deployed states, respectively.
  • body 73 is advanced over a guidewire via guidewire lumen 86 .
  • Radiopaque tip marker 84 may be used to aid in fluoroscopically guiding the device.
  • Balloon 82 then is inflated by a lumen within body 73 that communicates with port 78 .
  • Port 78 may communicate with a timing mechanism (not shown) that automatically deflates balloon 82 after a predetermined time, e.g., 15 seconds, to ensure that cerebral blood flow is not inhibited for a period so long as to cause cerebral compromise.
  • FIGS. 4D-4E illustrate mechanically deployable mechanism 92 comprising flexible wires 95 and impermeable coating 97 in contracted and deployed states, respectively.
  • Impermeable coating 97 comprises an elastomeric polymer, e.g., latex, polyurethane or polyisoprene.
  • the proximal end of deployable mechanism 92 is affixed to body 73 .
  • the distal end of mechanism 92 is affixed to distalmost section 99 , which in turn communicates with sliding member 93 that is configured to slide longitudinally within a lumen of body 73 .
  • Impermeable coating 97 conforms to the shape of wires 95 to provide a plug-shaped occlusive member, as shown in FIG. 4E .
  • Deployment knob 72 may communicate with a timing mechanism (not shown) that automatically releases mechanism 92 after a predetermined time.
  • occlusive device 121 comprises proximal hub 120 , hypo tube 127 , shaft 128 , balloon 136 and coil 142 .
  • Hypo tube 127 preferably comprises stainless steel, while shaft 128 preferably comprises a radiopaque material.
  • Balloon 136 is configured using a tubular balloon material, e.g., chronoprene, that is compliant in nature and provides a self-centering balloon when deployed.
  • the proximal end of balloon 136 is secured to radiopaque shaft 128 by band 132 and taper 130 .
  • the distal end of balloon 136 is affixed to coil 142 via taper 140 .
  • Core wire 122 is slidably disposed within hypo tube 127 so that its proximal end and is disposed in proximal hub 120 and its distal end is affixed to taper 140 . Fluid may be injected into the annulus surrounding core wire 122 so that the fluid exits into balloon 136 via inflation window 134 , thus permitting balloon 136 to expand radially and longitudinally. Core wire 122 , taper 140 and coil 142 may move distally to accommodate such linear extension. Stroke limiter 123 , disposed on the distal end of core wire 122 , ensures that balloon 136 does not extend longitudinally more a predetermined distance ‘x’.
  • occlusive device 151 comprises shaft 152 , balloon 158 , and coil 168 .
  • Shaft 152 preferably comprises a radiopaque material and connects to a hypo tube similar to that of FIG. 5A .
  • the proximal components for device 151 i.e., proximal to shaft 152 , are the same as the components that are proximal to shaft 128 in FIG. 5A .
  • Balloon 158 is constrained at its proximal end by band 156 having proximal balloon-marker 157 .
  • Taper 154 is provided on the proximal end of band 156 in alignment with the proximal end of balloon 158 .
  • the distal end of balloon 158 is everted, as shown in FIG. 5B , and secured with radiopaque band 160 that provides a fluoroscopic reference for the distal boundary of the balloon.
  • Taper 164 further secures the everted distal section, sandwiching between the first and second folds.
  • Core wire 150 is distally affixed to coil 168 having radiopaque marker 170 .
  • Lumen 159 communicates with an inflation port (not shown) at its proximal end and with inflation window 136 at its distal end. Lumen 159 permits the injection of fluids, e.g., saline, to deploy balloon 158 .
  • Core wire 150 is slidably disposed in the hypo tube and shaft 152 to prevent extension of balloon 158 up to a distance ‘x’, as indicated in FIG. 5A .
  • thrombectomy wire 200 having ball 202 affixed to its distal end is depicted in a contracted state within coil 204 .
  • thrombectomy wire 200 comprises a shape-memory retaining material, for example, a Nickel Titanium alloy (commonly known in the art as Nitinol).
  • Nitinol generally requires the setting of a custom shape in a piece of Nitinol, e.g., by constraining the Nitinol element on a mandrel or fixture in the desired shape, and then applying an appropriate heat treatments, which are per se known.
  • Coil 204 covers wire 202 along its length, up to ball 202 . As coil 204 is retracted proximally, wire 200 self-expands to a predetermined knot configuration, as. shown in FIG. 6B . In a preferred embodiment, the diameter of wire 200 is about 0.002 inches, the diameter of ball 202 is about 0.014 inches, and coil 204 is manufactured using platinum. It should be appreciated that an outer sheath may be used in place o ⁇ coil 204 , such that proximally retracting the outer sheath causes wire 200 to deploy.
  • thrombectomy wire 200 to snare a thrombus T, e.g., in middle cerebral artery MCA.
  • Thrombectomy wire 200 initially contracted within coil 204 , is advanced through a lumen of catheter 2 , then preferably is advanced in retrograde fashion via the internal carotid to the site of the cerebral lesion in the MCA.
  • controlled flow conditions i.e., conditions that will promote the flow of emboli toward catheter 2 , wire 200 and coil 204 pierce thrombus T, as shown in FIG. 6C .
  • Coil 204 then is retracted proximally with respect to wire 200 to self-deploy shape memory wire 200 at a location distal to thrombus T, as shown in FIG. 6D .
  • Wire 200 then is retracted to snare thrombus T, and ball 202 of wire 200 facilitates removal of the lesion.
  • thrombectomy wire 205 having distal ball 208 is delivered in a contracted state within slidable sheath 206 .
  • Thrombectomy wire 205 is configured to self-deploy to a predetermined shape, e.g., via use of a shape memory material, upon proximal retraction of sheath 206 .
  • Coil 207 overlays slidable sheath 206 and is. affixed to ball 208 at points 209 a and 209 b , e.g., via a solder or weld.
  • Sheath 206 is initially provided in a distalmost position such that it abuts ball 208 and constrains wire 205 along its length. Sheath 206 advantageously enhances the distal pushability of the device, particularly when the device is advanced though an occlusion.
  • sheath 206 Upon positioning the distal end of wire 205 at a location distal to the occlusion, sheath 206 is retracted proximally to cause wire 205 to self-deploy to a knot-shaped configuration, as depicted in FIG. 6F .
  • Coil 207 affixed to ball 208 of wire 205 , conforms to the shape of wire 205 .
  • the deployed knot-shaped device then is proximally retracted to snare the occlusion, according to methods described hereinabove.
  • thrombectomy wire 210 comprises a plurality of intersecting ⁇ oops that deploy upon retraction of a coil or sheath.
  • Hoops 212 and 214 may be orthogonal to each other, as shown in FIG. 7A .
  • the hoops are designed to form a knot-shape to snare a thrombus in combination with ball 216 .
  • there may be a series of intersecting hoops, as shown in FIG. 7B .
  • Thrombectomy wire 220 comprises first knot 222 and second knot 224 separated by a distance ‘y’, although it will be obvious that any variation in the number of knots and their shapes are intended to fall within the scope of the present invention.
  • thrombectomy wire 230 comprises spiral-shaped distal section 232 .
  • the spiral shape is formed from a series of planar hoops, the diameter of hoops being slightly smaller with each successive hoop.
  • the hoops of spiral 232 are depicted as being orthogonal to the main axis of wire 230 .
  • Elbow 234 defines a bent section that connects main wire section 236 to first hoop 238 .
  • elbow 234 is orthogonal to main wire section 236 , however, it may be provided at any angle.
  • wire 240 may comprise a plurality of spiral-shaped sections 242 and 244 separated by a distance ‘z’.
  • thrombectomy wire 250 comprise a plurality of petal-shaped sections that deploy upon retraction of a coil or sheath.
  • petal-shaped sections 252 and 254 are orthogonal to each other, however, they may be provided at any angle with respect to main axis 256 and each other, and any number of petal-shaped sections may be provided.
  • Device 260 removes a lesion by organizing the fibrin strands of the lesion around the deployable wires using a rotational motion. Exemplary method steps for using the embodiments described in FIGS. 8A-8D are described in FIGS. 10 hereinbelow.
  • thrombectomy device 260 comprises at least one deployable wire 262 affixed at its proximal and distal ends at points 266 and 264 , respectively.
  • Deployable wire 262 is initially contracted within coil 268 , and when tubular member 268 , e.g., a coil or sheath, is retracted proximally, deployable wires 262 self-expand to a predetermined shape, as shown.
  • tubular member 268 e.g., a coil or sheath
  • deployable wires 262 self-expand to a predetermined shape, as shown.
  • the fibrin strands of the thrombus will become engaged with and wrap around deployable wires 262 .
  • alternative thrombectomy device 270 comprises at least one deployable wire 274 that is distally affixed to wire 270 at point 276 .
  • the proximal end of wire 274 is secured to sliding member 272 , which slides longitudinally over wire 271 .
  • deployable wire 274 either radially outwardly deflects, as shown, or flattens out for a contracted position.
  • thrombectomy device 280 comprises deployable wire 282 configured to form a plurality of loops 285 around shaft 283 .
  • the distal end of deployable wire 282 is affixed to shaft 283 at point 284 , which may serve as an atraumatic tip for guiding the device and piercing the thrombus.
  • the proximal end of deployable wire 282 is affixed to tube 281 .
  • Tube 281 spans the length of the device and has a proximal end that is manipulated by the physician.
  • Distally advancing tube 281 over shaft 283 deploys loops 285 , as shown, while proximally retracting tube 281 with respect to shaft 283 contracts loops 285 .
  • rotating the device about its axis will cause loops 285 of wire 282 to engage the thrombus and wrap the fibrin strands about the device, as described in FIGS. 10 hereinbelow.
  • thrombectomy device 290 comprises a plurality of shape-memory, arrowhead-shaped wires 292 that are distally affixed to each other at point 294 and proximally affixed at junction 298 .
  • Wires 292 are initially contracted within tubular member 296 , e.g., a coil or sheath, and upon proximal retraction of tubular member 296 , wires 292 self-deploy to the configuration shown.
  • thrombectomy device, 300 comprises proximal segment 306 , catheter 302 , and distal segment 304 .
  • Proximal segment 306 comprises thumb ring 308 , proximal body 310 , and deployment knob 312 that slides longitudinally within slot 314 .
  • Distal segment 304 comprises at least one deployable wire 316 and atraumatic tip 318 .
  • FIG. 9B provides a schematic view of distal segment 304 .
  • Deployable wire 316 preferably comprises a shape memory material that communicates with deployment knob 312 at its proximal end, as described in FIG. 9C hereinbelow.
  • the distal end of deployable wire 316 is affixed to atraumatic tip 318 , e.g., using a solder or weld.
  • Deployable wire 316 is delivered in a contracted state, i.e., such that it does not substantially extend radially beyond catheter. 302 .
  • wire 316 Upon actuation of deployment knob 312 , self-expands via holes 317 to form a whisk-type element, as shown.
  • Catheter 302 may be provided with one or more working lumens that. communicate with delivery port 305 to permit the delivery of fluids, e.g., saline or other drugs that facilitate clot removal.
  • FIG. 9C provides a schematic view of proximal segment 306 .
  • the distal end of deployable wire 316 is configured to deploy from catheter 302 .
  • the proximal end of catheter 302 is affixed to outer shaft 322 , which preferably has a square cross-section.
  • Outer shaft 322 is keyed to inner shaft 320 .
  • Inner shaft 320 is keyed to slidably more actuator 323 , so that rotational motion of one element causes rotation of the other.
  • Catheter 302 further is affixed to retainer 315 , which permits catheter 302 to rotate freely relative to proximal body 310 .
  • Thumb ring 308 communicates with actuator 323 via joint 321 .
  • Joint 321 permits rotational motion of actuator 323 with respect to thumb ring 308 .
  • Actuator 323 is affixed to rotational member 326 at its distal end, which in turn is affixed to inner shaft 320 .
  • Rotational member 326 comprises knob 327 that is configured to slidably rotate within groove 328 in the wall of body 310 .
  • Deployable wire 316 is deployed by sliding deployment knob 312 within slot 314 .
  • Deployment knob 312 comprises a rounded pin that engages with a groove of ring 324 . This engagement distally advances ring 324 within slot 325 of catheter 302 .
  • Deployable wire 316 is affixed to ring 324 , such that distally advancing ring 324 via deployment knob 312 allows wire 316 to self-deploy.
  • the rounded pin engagement between knob” 312 and the groove of ring 324 further permits free axial rotation of ring 324 while knob 312 is stationary.
  • thumb-ring 308 With wire 316 deployed, thumb-ring 308 is depressed with a force that overcomes a resistance force provided by spring 330 . Depressing thumb ring 308 in turn causes rotational member 326 to be advanced distally via groove 328 . When a thumb force is no longer applied, the resistance of spring 330 then pushes rotating member 326 in a proximal direction via groove 328 . This in turn causes rotation of rotational member 326 , inner shaft 320 , outer shaft 322 and catheter 302 . The rotation of catheter 302 generates rotation of thrombectomy wire 316 .
  • the rotation of thrombectomy wire 316 may be clockwise, counterclockwise, or a combination thereof by manipulating the profile of groove 328 .
  • the rotational speed may be controlled by varying the resistance of spring 330 , and the duration of rotation can be controlled by varying the length in which rotational member 326 can longitudinally move.
  • another force transmission means e.g., a motor, may be coupled to the proximal end to provide for controlled axial rotation of catheter 302 .
  • FIGS. 10 illustrate method steps for removing thrombi using any of the thrombectomy devices described in FIGS. 8-9 .
  • catheter 302 is advanced through catheter 2 of FIG. 2 , then advanced in a retrograde fashion toward the occlusion.
  • Catheter 302 may be advanced via the internal carotid artery to treat a lesion T located in a cerebral vessel V, e.g., the middle cerebral artery.
  • Atraumatic tip 318 serves to protect vessel walls as catheter 302 is advanced through tortuous anatomy.
  • flow control devices 8 of FIG. 2 are deployed to cause retrograde blood to flow in the directions indicated.
  • Tip 318 of catheter 302 then is advanced to pierce thrombus T, as shown in FIG. 10B .
  • Deployment knob 312 of FIG. 9 then is actuated to deploy at least one deployable wire 316 within thrombus T.
  • Thumb ring 308 then is depressed, resulting in the controlled rotation of deployable wire 316 , such that the wire engages the fibrin strands of thrombus T.
  • the diameter of thrombus T decreases, as shown in FIG. 10D .
  • deployable wire 316 is designed such that it does not contact the inner wall of vessel V. Once the thrombus T is sufficiently wound about deployable wire 316 , as shown in FIG. 1E , catheter 302 may be retracted into catheter 2 .
  • FIG. 11 an alternative embodiment of the present invention is described wherein a second catheter is advanced to a location in closer proximity to the occlusive lesion.
  • Main catheter 340 having distal occlusive element 342 is positioned, for example, in the common carotid artery, as described in FIG. 2 .
  • Recovery catheter 344 having distal occlusive element 346 and radiopaque marker 347 is configured to telescope within the lumen of main catheter 340 .
  • main catheter 340 is disposed in the common carotid artery. Retrograde flow then is established using venous return line 52 of FIG. 3A according to methods described hereinabove.
  • a 0.014 inch neuro guidewire 350 then is advanced via the lumen of main catheter 340 to the site of the cerebral occlusion, and neuro guidewire 350 is disposed distal to the lesion.
  • an occlusion (not shown) would be located approximately within an interval ‘L’, e.g., in the middle cerebral artery.
  • Recovery catheter 344 then is advanced distally over neuro guidewire 350 and is positioned proximal to occlusion ‘L’. Upon positioning recovery catheter 344 , occlusive distal element 346 is deployed.
  • Neuro catheter 348 then is advanced over neuro guidewire 350 , and the distal end of neuro catheter 348 is disposed at a location distal to occlusion ‘L’, as shown.
  • Neuro guidewire 350 then is retracted proximally and removed from within neuro catheter 348 , which comprises a relatively small lumen. With neuro guidewire 350 removed, a thrombectomy wire is advanced distally through the lumen of neuro catheter 348 , and the thrombectomy wire takes the place of guidewire 350 in FIG. 11 .
  • Neuro catheter 348 then is proximally retracted, and thrombectomy wire 350 is deployed to treat the occlusion according to methods described hereinabove.
  • Recovery catheter 344 comprises at least one blood venting hole 345 .
  • the established retrograde flow through catheter 344 using venous return line 52 induces retrograde flow in at least the internal carotid artery via blood venting hole 345 .
  • Flow into venting hole 345 may be manipulated by actuating inner sheath 349 , e.g., by longitudinally sliding inner sheath 349 within catheter 344 , or rotating inner sheath 349 relative to its longitudinal axis.
  • recovery catheter 344 is positioned in close proximity to the lesion, so that wire 348 and any emboli generated are immediately confined within recovery catheter 344 . Furthermore, advancing recovery catheter 344 via the internal carotid artery eliminates the need for deploying balloon 10 of FIG. 2 in the external carotid artery.
  • FIGS. 12 a further alternative embodiment of the present invention is described wherein a second catheter is advanced to a location in closer proximity to the occlusive lesion.
  • Main catheter 360 having distal occlusive element 362 is positioned, for example, in the common carotid artery, as described in FIG. 2 .
  • Recovery catheter 364 comprises a wire weave configuration and may be manufactured using a shape memory material, e.g., Nitinol, as described hereinabove.
  • Recovery catheter 364 further comprises blood impermeable membrane 365 , such as latex, polyurethane or polyisoprene, that encloses the wire weave of recovery catheter 364 .
  • the elastic properties of blood impermeable membrane 365 allow it to conform to the contracted and expanded states of recovery catheter 364 .
  • Recovery catheter 364 is advanced in a contracted state within outer sheath 366 .
  • outer sheath 366 is retracted proximally to cause occlusive distal section 368 to self-expand to a predetermined deployed configuration, as shown in FIG. 12A .
  • Occlusive distal section 368 may be sized for different vessels, e.g., the middle cerebral arteries, so that the distal end of recovery catheter 364 is disposed proximal to an occlusion, e.g., as depicted at location ‘L’.
  • Mouth 369 provides a relatively large distal opening, i.e., flush with the inner wall of the targeted vessel.
  • Neuro catheter 370 then is advanced over neuro guidewire 372 , as described hereinabove in FIG. 11 , and a thrombectomy wire is exchanged for neuro guidewire 372 .
  • Neuro catheter 370 is proximally retracted, and thrombectomy wire 372 removes the occlusion at location ‘L’ according to methods described hereinabove.
  • thrombectomy wire 372 is retracted into mouth 369 , along with any” emboli generated during the procedure.
  • FIGS. 12B-12D illustrate a method for effectively collapsing mouth 369 proximally to distally, as shown.
  • FIG. 12B shows outer sheath 366 having radiopaque marker 367 in a proximally retracted position that allows occlusive distal section 368 to deploy.
  • outer sheath 366 is advanced distally to collapse mouth 369 , as shown sequentially in FIGS. 12C-12D . This effectively confines thrombi and/or emboli within mouth 369 .
  • flow control devices 400 having controllers 402 are introduced into the patient's vasculature in a contracted state, e.g., via the radial or brachial arteries, and preferably are positioned in the patient's left subclavian artery and brachiocephalic trunk, as shown. It will be appreciated by those skilled in the art that varying the number of flow control devices and their placements is intended to fall within the scope of the present invention. Blood flow occurs in the directions indicated.
  • catheter 404 of FIG. 3A is positioned in the common carotid artery CCA using guide wire 406 .
  • Catheter 404 is positioned proximal to the carotid bifurcation, as shown, preferably in the hemisphere in which the cerebral occlusion is located.
  • Balloon 408 for example, as described in FIGS. 5 , then is disposed in the external carotid artery and deployed, as shown in FIG. 13C .
  • distal occlusive element 412 of catheter 404 is deployed to occlude ante grade flow in the selected CCA.
  • Venous return catheter 52 of FIG. 3A then is placed in a remote vein, such that negative pressure in venous return catheter 52 during diastole establishes a continuous flow through the lumen of catheter 404 .
  • a thrombectomy wire 414 for example, as described in FIGS. 6-10 , is advanced through catheter 404 and into the cerebral vasculature via the ICA.
  • Thrombectomy wire 414 has been advanced to a location just proximal to thrombus T, for example, in middle cerebral artery MCA.
  • flow control devices 400 then are deployed using controller 402 to form occlusive elements 420 , as shown in FIG. 13F .
  • occlusive elements 420 may be selectively placed at other locations to permit and/or inhibit flow into the selected locations of the cerebral vasculature.
  • occlusive elements 420 controls flow in the Circle of Willis, as shown in FIG. 13G .
  • emboli that are generated will be directed in a retrograde fashion toward catheter 404 the left internal carotid artery.
  • the distal end of thrombectomy wire 414 then pierces thrombus T and deployable knot 416 is deployed distal to the thrombus, as shown in FIG. 13G .
  • other thrombectomy wire configurations may be used to treat the lesion, as described in FIGS. 6-10 .
  • Deployable knot 416 of thrombectomy wire 414 snares thrombus T, as shown in FIG. 13H , and subsequently is retracted into catheter 404 . Any emboli generated during the procedure will be directed into catheter 404 via the established retrograde flow. Occlusive elements 420 , distal occlusive element 412 , and external carotid occlusive device 408 then are contracted, and catheter 404 may be removed from the patient.
  • FIGS. 13 may be used in combination with any of the apparatus described hereinabove.
  • recovery catheters 344 and 364 of FIGS. 11 and 12 may be advanced through catheter 404 of FIGS. 13 .
  • any of the snaring thrombectomy devices of FIGS. 7 or the rotating thrombectomy devices of FIGS. 8 may be used in place of thrombectomy wire 414 as depicted.
  • any of the occlusive devices described in FIGS. 4B-4E and FIGS. 5A-5B may be used in place of occlusive elements 420 and 408 , respectively.
  • catheter 430 may be configured for use in any of the carotid and vertebral arteries.
  • Catheter 430 comprises blood intake port 432 , distal occlusive element 436 and radiopaque tip marker 435 .
  • Occlusive element 436 comprises proximal and distal tapers 438 and 440 , respectively.
  • Inner sheath 434 is configured for longitudinal sliding motion within catheter 430 .
  • Inner sheath 434 is initially provided in a distalmost position that covers blood intake port 432 in a closed state, as shown in FIG. 14A .
  • Deployment of occlusive element 436 inhibits antegrade blood flow in vessel V, at which time therapeutic drugs and/or devices may be delivered to site of the occlusion via lumen 437 .
  • Retrograde blood flow in vessel V is induced by placing venous return catheter 52 of FIG. 3A into a remote vein, according to methods described hereinabove.
  • the retrograde flow through lumen 437 induces retrograde flow distal to occlusive element 436 .
  • Distal taper 440 facilitates retrograde blood flow into lumen 437 .
  • inner sheath 434 may be retracted proximally to expose blood intake port 432 , as shown in FIG. 14B . This permits antegrade flow to enter intake port 432 and continue flowing in an antegrade direction distal to occlusive element 436 .
  • Proximal taper 438 is configured to enhance antegrade blood flow into intake port 432 .
  • Cerebral flow manipulation may be enhanced by placing a first catheter in accordance with FIGS. 14 in a common carotid artery and a second catheter in a vertebral artery, each on the hemisphere of the occlusion.
  • FIG. 15 depicts apparatus suitable for controlling cerebral flow when utilizing one carotid and one vertebral catheter in combination.
  • catheters 450 and 470 are configured to be disposed in the common carotid and vertebral arteries, respectively.
  • two vertebral catheters may be used, i.e., one in each of the vertebral arteries, in combination with the carotid catheter.
  • Catheters 450 and 470 each comprises a plurality of lumens.
  • Inner sheaths 456 and 476 are configured to slide longitudinally within an outermost lumen of their respective catheters.
  • Inner sheaths 456 and 476 communicate with deployment knobs 452 and 472 .
  • Sliding deployment knobs 452 and 472 within slots 454 and 474 controls movement of inner sheaths 456 and 476 , respectively.
  • Inflation ports 462 and 482 communicate with lumens of their respective catheters.
  • Working lumens 458 , 460 , 478 and 480 provide each catheter with two working lumens, e.g., for advancing guide wires and thrombectomy wires, and may be provided with hemostatic valves, for example, Touhy-Borst connectors.
  • Biocompatible tubing 459 and 461 enable fluid communication between retrograde flow controller 465 and lumens of catheter 450 and 470 , respectively. Retrograde flow controller 465 further communicates with venous return line 52 of FIG. 3A via tubing 463 .
  • Switch 467 of retrograde flow controller 465 permits tubing 459 and 461 to communicate with retrograde flow of tubing 463 singularly or in combination, or switch 467 may inhibit retrograde flow altogether. For example, when retrograde flow is induced in tubing 463 via venous return line 52 , either one of tubing 459 and 461 , both, or neither may experience retrograde flow based on the position of switch 467 .
  • the apparatus described in FIG. 15 allow a physician to provide either retrograde, antegrade or hemostatic flow from two opposing cerebral locations, i.e., the carotid and vertebral arteries.
  • the lumens of the vertebral and/or carotid catheters may be perfused with blood or saline under pressure to manipulate flow at selected cerebral locations.
  • the apparatus further allows for the injection of therapeutic drugs and/or thrombectomy devices. Chilled blood or saline may be delivered via either of the carotid and vertebral catheters to induce mild hypothermia at selected cerebral locations, while drug agents may be used to selectively alter the pressure gradients.
  • lytic agents may be delivered via either of the carotid or vertebral catheters to aid in the disintegration of the occlusion.
  • Such lytic agents preferably are used in combination with the flow manipulation techniques in accordance with the present invention, to direct emboli resulting from the lytic process into the removal catheter(s).
  • FIGS. 16 method steps are described to manipulate cerebral flow in a variety of ways using a combination of carotid and vertebral catheters.
  • a first catheter 500 comprising occlusive element 502 and blood intake port 504 is disposed in the left common carotid artery CCA.
  • Inner sheath 506 is provided in a distalmost position to prevent fluid from entering intake port 504 , and occlusive element 502 is deployed to occlude antegrade flow.
  • Balloon 508 e.g., as described in FIGS. 5 , then is deployed in the ECA.
  • a second catheter 520 comprising occlusive element 522 and blood intake port 524 is disposed in the left and/or right vertebral artery VA.
  • a second catheter 520 comprising occlusive element 522 and blood intake port 524 is disposed in the left and/or right vertebral artery VA.
  • Inner sheath 526 is provided in a distalmost position to prevent fluid from entering intake port 544 , and occlusive element 522 is deployed to occlude antegrade flow.
  • Venous return line 52 of FIG. 3A then is placed in a remote vein, according to methods described hereinabove, and retrograde flow may be induced either in the ICA, VA, or both arteries based on switch 467 of FIG. 15 .
  • switch 467 is set to a position that permits retrograde flow to be induced in both the carotid and vertebral catheters.
  • any of the flow control devices described in FIGS. 4 optionally may be deployed to occlude flow in the opposing carotid and vertebral arteries, according to methods described hereinabove. In this example, this ensures that blood flow is controlled in the left hemisphere.
  • Thrombectomy wire 510 having deployable knot 512 then is advanced into the MCA via the ICA and snares thrombus T, according to methods described hereinabove.
  • Emboli E generated during the procedure are directed toward either one of catheters 500 and 520 for removal.
  • the use of two catheters in combination provides for improved aspiration of the targeted vessel, in this case, the MCA.
  • deployable knob 472 of FIG. 15 is proximally retracted to retract inner sheath 526 and expose intake port 524 of catheter 520 .
  • Switch 467 of retrograde flow controller 465 is positioned for retrograde flow only through catheter 500 . This allows antegrade flow in vertebral artery VA to enter intake port 524 and continue flowing in an antegrade direction into basilar artery BA and toward the MCA via the path indicated. The combination of antegrade flow from the left VA and either antegrade or retrograde flow from the left ICA directs emboli E generated in the MCA to flow primarily into catheter 500 .
  • therapeutic drugs may be delivered to the MCA when switch 467 of FIG. 15 inhibits venous flow into both catheters 500 and 520 , and each of blood intake ports 504 and 524 are closed.
  • Therapeutic drugs may be delivered via either port 458 or 478 into the MCA, or mild hypothermia may be induced by introducing chilled blood or saline.
  • retrograde flow controller 465 and deployable knobs 452 and 472 may provide for any combination of antegrade, retrograde, or hemostatic flow in the carotid and vertebral arteries.
  • therapeutic drugs, thrombectomy devices, cardioplegic and/or brain chilling agents may be delivered under a variety of controlled cerebral flow conditions.
  • a neuro guidewire and neuro catheter as described in FIGS. 11 and 12 A hereinabove, may be used in conjunction with thrombectomy wire 510 of FIGS. 16 .

Abstract

Apparatus and methods for treatment of stroke are provided. In a preferred embodiment, the present invention disposes at least one catheter having a distal occlusive member in either the common carotid artery (CCA) or both the vertebral artery (VA) and the CCA on the hemisphere of the cerebral occlusion. Blood flow in the opposing carotid and/or vertebral arteries may be inhibited. Retrograde or antegrade flow may be provided through either catheter independently to effectively control cerebral flow characteristics. Under such controlled flow conditions, a thrombectomy device may be used to treat the occlusion, and any emboli generated are directed into the catheter(s).

Description

    RELATED APPLICATIONS
  • The present application is a divisional of copending U.S. patent application Ser. No. 09/972,231 filed Oct. 4, 2001.
  • FIELD OF THE INVENTION
  • The present invention relates to improved apparatus and methods for treatment of stroke. More specifically, the apparatus and methods of the present invention are directed to treating stroke by controlling cerebral blood flow and removing thrombi and/or emboli.
  • BACKGROUND OF THE INVENTION
  • Cerebral occlusions that lead to stroke require swift and effective therapy to reduce morbidity and mortality rates associated with the disease. Many current technologies for treating stroke are inadequate because emboli generated during the procedure may travel downstream from the original occlusion and cause ischemia. There is currently a need for a stroke treatment system that provides a swift and efficient treatment for occlusions while simultaneously controlling cerebral flow characteristics.
  • In the initial stages of stroke, a CT scan or MRI may be used to diagnose the cerebral occlusion, which commonly occurs in the middle cerebral arteries. Many current technologies position a catheter proximal to the occlusion, then deliver clot dissolving drugs to treat the lesion. A drawback associated with such technology is that delivering drugs may require a period of up to six hours to adequately treat the occlusion. Another drawback associated with lytic agents (i.e., clot dissolving agents) is that they often facilitate bleeding.
  • When removing thrombus using mechanical embolectomy devices, it is beneficial to engage the thrombus and remove it as cleanly as possible, to reduce the amount of emboli that are liberated. However, in the event that emboli are generated during mechanical disruption of the thrombus, it is imperative that they be subsequently removed from the vasculature.
  • Many current drug delivery and mechanical treatment methods are performed under antegrade flow conditions. Such treatment methods do not attempt to manipulate flow characteristics in the cerebral vasculature, e.g, the Circle of Willis and communicating vessels, such that emboli may be removed. Accordingly, there remains a need to provide effective thrombus and emboli removal from the cerebral vasculature while simultaneously controlling flow within that vasculature.
  • U.S. Pat. No. 6,161,547 to Barbut (Barbut '547) describes a technique for enhancing flow in the cerebral vasculature in treating patients with acute stroke or other cerebrovascular disease. The technique involves: (1) positioning a first tubular member in a vascular location suitable for receiving antegrade blood flow; (2) positioning a second tubular member in a contralateral artery of the occlusion (e.g., for an occlusion located in the left common carotid artery the second tubular member is placed in the right common carotid artery); and coupling the first tubular member to the second tubular member using a pump and filter.
  • The first tubular member receives antegrade blood flow and channels the blood to the pump and filter, where the blood then is reperfused via the second tubular member into the contralateral artery, thus increasing blood flow to the opposing hemisphere of the brain. The first and second tubular members may include balloons disposed adjacent to their distal ends.
  • The techniques described in the foregoing patent have several drawbacks. For example, if the first balloon of the first tubular member is deployed in the left common carotid artery, as shown in FIG. 7C, aspiration of blood from the vessel between the balloon and the occlusion may cause the vessel to collapse. On the other hand, if the balloon is not deployed, failure to stabilize the distal tip may result in damage to the vessel walls. In addition, failure to occlude the vessel may permit antegrade blood flow to diverted into that apparatus, rather than blood distal to the first tubular member.
  • The Barbut '547 patent further discloses that inflating the balloon of the second tubular member may assist in controlling the flow to the contralateral artery or provide more efficient administration of pharmacotherapy to the cerebral tissues. However, when that balloon is deployed, the contralateral artery may be starved of sufficient flow, since the only other flow in that artery is that aspirated through the first tubular member. On the other hand, if the balloon of the second tubular member is not inflated, no flow control is possible.
  • A method for removing cerebral occlusions is described in U.S. Pat. No. 6,165,199 to Barbut (Barbut '199). This patent describes a catheter having an aspiration port at its distal end that communicates with a vacuum at its proximal end. A perfusion port disposed in a lateral surface of the catheter may be used to enhance antegrade flow in collateral arteries. In use, the aspiration port is positioned proximal to an occlusion to provide a direct suction effect on the occlusion. The perfused flow in collateral arteries is intended to augment retrograde flow distal to the occlusion, such that the occlusion is dislodged via the pressure and directed toward the aspiration port. A chopping mechanism, e.g., an abrasive grinding surface or a rotatable blade, coupled to the aspiration port recognizes when the aspiration port is clogged. The chopping mechanism then engages to break up the occlusion and permit it to enter the aspiration port in smaller pieces.
  • The device described in the Barbut '199 patent has several disadvantages. First, the use of a vacuum to aspirate the occlusion requires an external pressure monitoring device. The application of too much vacuum pressure through the aspiration port may cause trauma, i.e., collapse, to the vessel wall. Also, because the system is intended to dislodge the occlusion using a pressure differential, a chopping mechanism is required to prevent the entire mass from clogging the aspiration port. The use of a chopping mechanism, however, may generate such a large quantity of emboli that it may be difficult to retrieve all of the emboli. In addition, emboli generated by the action of the chopping mechanism may accumulate alongside the catheter, between the aspiration port and the distal balloon. Once this occurs, it is unclear how the emboli will be removed.
  • Yet another drawback of the device described in the Barbut '199 patent is that high-pressure perfusion in collateral arteries may not augment retrograde flow distal to the occlusion as hypothesized. The patent indicates that high-pressure perfusion in collateral arteries via side ports in the catheter may be sufficient to cause an increase in pressure distal to the occlusion. Antegrade blood flow from the heart in unaffected arteries, e.g., other vertebral and/or carotid arteries, may make it difficult for the pressure differential induced in the contralateral arteries to be communicated back to the occluded artery in a retrograde fashion.
  • Other methods for treating ischemic brain stroke have involved cerebral retroperfusion techniques. U.S. Pat. No. 5,794,629 to Frazee describes a method that comprises at least partially occluding the first and second transverse venous sinuses and introducing a flow of the patient's arterial blood to a location distal to the partial venous occlusions. As described in that patent, the-infusion of arterial blood into the venous sinuses provides a retrograde venous flow that traverses the capillary bed to oxygenate the ischemic tissues and at least partially resolve ischemic brain symptoms.
  • One drawback associated with the technique described in the Frazee patent is that the pressure in the transverse venous sinuses must be continuously monitored to ensure that cerebral edema is avoided. Because the veins are much less resilient than arteries, the application of sustained pressure on the venous side may cause brain swelling, while too little pressure may result in insufficient blood delivered to the arterial side.
  • In addition to the foregoing methods to augment cerebral perfusion, several methods are known for mechanically removing clots to treat cerebral occlusions. U.S. Pat. No. 5,895,398 to Wensel et al. describes a shape-memory coil affixed to an insertion mandrel. The coil is contracted to a reduced profile state within the lumen of a delivery catheter, and the catheter is used to cross a clot. Once the coil is disposed distal to the clot, the coil id deployed. The coil then is retracted proximally to engage and remove the clot.
  • A primary drawback associated with the Wensel device is that the deployed coil contacts the intima of the vessel, and may damage to the vessel wall when the coil is retracted to snare the occlusion. Additionally, the configuration of the coil is such that the device may not be easily retrieved once it has been deployed. For example, once the catheter has been withdrawn and the coil deployed distal to the occlusion, it will be difficult or impossible to exchange the coil for another of different dimensions.
  • U.S. Pat. No. 5,972,019 to Engelson et al. describes a deployable cage assembly that may be deployed distal to a clot. Like the Wensel device, the Engelson device is depicted as contacting the intima of the vessel, and presents the same risks as the Wensel device. In addition, because the distal end of the device comprises a relatively large profile, the risk of dislodging emboli while crossing the clot is enhanced, and maneuverability of the distal end of the device through tortuous vasculature may be reduced.
  • In view of these drawbacks of previously known clot removal apparatus and methods, it would be desirable to provide apparatus and methods for controlling hemodynamic properties at selected locations in the cerebral vasculature, e.g., the Circle of Willis and communicating vessels.
  • It also would be desirable to provide apparatus and methods for removal and recovery of thrombi and/or emboli above the carotid bifurcation.
  • It still further would be desirable to provide apparatus and methods that quickly and efficiently treat cerebral occlusions.
  • It still further would be desirable to provide apparatus and methods for selectively providing retrograde and/or antegrade flow to desired regions in the cerebral vasculature to effectively remove emboli.
  • SUMMARY OF THE INVENTION
  • In view of the foregoing, it is an object of the present invention to provide apparatus and methods for controlling hemodynamic properties at selected locations in the cerebral vasculature.
  • It is also an object of the present invention to provide apparatus and methods for removal and recovery of thrombi and/or emboli above the carotid bifurcation.
  • It is a further object of the present invention to provide apparatus and methods that quickly and efficiently treat cerebral occlusions.
  • It still a further object of the present invention to provide apparatus and methods for selectively providing retrograde and/or antegrade flow to desired regions in the cerebral vasculature to effectively remove emboli.
  • These and other objects of the present invention are accomplished by providing a stroke treatment system comprising an emboli removal catheter and one or more flow control devices suitable for manipulating blood flow in the cerebral vasculature. The stroke treatment system may facilitate the introduction and subsequent removal of clot lysing agents, or further comprise a thrombectomy element.
  • In a preferred embodiment, the emboli removal catheter is transluminally inserted and disposed in the common carotid artery CCA, and comprises a flexible catheter having an occlusive member disposed on its distal end. The occlusive member is configured to be deployed to anchor the catheter and occlude antegrade flow in the CCA. A separate occlusive element is configured to pass through a lumen of the emboli removal catheter, and is deployed in the external carotid artery ECA to occlude flow through that vessel.
  • One or more flow control devices, each having a rapidly deployable occlusive member, then are positioned at selected locations, e.g., in the subclavian arteries, and may be deployed to isolate or redistribute flow through the cerebral vasculature. Preferably, the flow control devices occlude blood flow in the vertebral and carotid arteries in the hemisphere in which the occlusion is not located. This temporarily influences flow in the opposing hemisphere. Preferably, the flow control devices are provided in sufficient number that, when deployed, the flow control devices substantially influence the flow dynamic of mid-cerebral artery.
  • Once the foregoing components have been deployed, a lysing agent may be introduced into the vessel through a lumen of the emboli removal catheter. After an appropriate period, the occlusive members on one or more of the flow control devices may be collapsed to cause retrograde flow through the cerebral vasculature sufficient to flush the lysing agent and any emboli or debris from the vasculature into the emboli removal catheter. The stroke treatment system and flow control devices may then be withdrawn from the patient's vasculature.
  • Alternatively, a thrombectomy element may be advanced transluminally via the ICA to a position just proximal of a cerebral occlusion, e.g., in the middle cerebral artery, after placement (but prior to deployment) of the flow control devices. The flow control devices then are deployed to selectively and temporarily redistribute or suspend flow in the cerebral vasculature. The thrombectomy element preferably is advanced to the site of the cerebral occlusion through a lumen of the emboli removal catheter.
  • With flow controlled throughout the Circle of Willis and therefore the communicating mid-cerebral artery, the thrombectomy element then is engaged with the lesion. Actuation of the thrombectomy element preferably causes mechanical disruption of the emboli or thrombus, after which the element is retracted into the emboli removal catheter. By selectively de-actuating one or more of the flow control devices, retrograde or redistributed flow may be generated in the vasculature that cases emboli liberated during actuation of the thrombectomy element to be directed into the emboli removal catheter. The flow control devices then are withdrawn to reestablish antegrade blood flow.
  • In a further alternative embodiment, a second emboli removal catheter may be disposed in a vertebral artery in lieu of one of the flow control devices. In this embodiment, the lumen of the second emboli removal catheter may be perfused with blood or saline under pressure to induce retrograde flow elsewhere in the cerebral vasculature, such as in the carotid or vertebral arteries. Additionally, chilled blood and/or drug agents may be delivered via the second catheter to induce mild hypothermia and/or altered pressure gradients at selected cerebral locations.
  • The second emboli removal catheter may be used to enhance flow manipulation in the Circle of Willis and communicating vessels to facilitate removal of emboli via either retrograde or antegrade flow either independently or, or simultaneously with, use of the first emboli removal catheter.
  • BRIEF DESCRIPTION OF THE DRAWINGS
  • Further features of the invention, its nature and various advantages will be more apparent from the accompanying drawings and the following detailed description of the preferred embodiments, in which:
  • FIG. 1 provides a schematic overview of the portion of the vasculature in which the apparatus and methods of the present invention are intended for use;
  • FIG. 2 provides an overview of the apparatus of the present invention deployed in a patient's vasculature;
  • FIGS. 3A-3D are, respectively, a schematic view, and detailed side and sectional views of the distal end of an emboli removal catheter of the present invention;
  • FIGS. 4A-4E provide detailed views of the proximal and alternative distal ends of the flow control devices of the present invention contracted and expanded: states;
  • FIGS. 5A-5B are views of alternative embodiments of low profile occlusive elements for occluding flow in the external carotid arteries;
  • FIGS. 6A-6F depict thrombectomy wires having shape memory properties in contracted and deployed states;
  • FIGS. 7A-7E illustrate alternative configurations for the thrombectomy wire of FIGS. 6;
  • FIGS. 8A-8D illustrate thrombectomy wires configured to engage the fibrin strands of a thrombus;
  • FIGS. 9A-9C describe an alternative thrombectomy device configured to engage the fibrin strands of a thrombus;
  • FIGS. 10A-10E illustrate method steps for removing an occlusion using the apparatus of FIGS. 9;
  • FIG. 11 describes a telescoping catheter configured to be advanced through the main catheter;
  • FIGS. 12A-12D describe a telescoping catheter having an expandable distal section configured to be advanced through the main catheter;
  • FIGS. 13A-13H illustrate method steps for controlling cerebral blood flow and removing thrombi and/or emboli in accordance with the present invention;
  • FIGS. 14A-14B describe a catheter having an intake port configured to provide for retrograde and/or antegrade flow in either of the carotid or vertebral arteries;
  • FIG. 15 illustrates a proximal assembly suitable for controlling retrograde and antegrade flow in the carotid and vertebral catheters of FIG. 14; and FIGS. 16A-16B provide examples of manipulating cerebral flow using a combination of carotid and vertebral catheters, each having antegrade and retrograde flow potential.
  • DETAILED DESCRIPTION OF THE INVENTION
  • Referring to FIG. 1, a schematic of the pertinent vasculature relating to the present invention is provided. Many cerebral obstructions that lead to stroke reside in the middle cerebral arteries MCA. To treat obstructions in the MCA, one approach involves percutaneously and transluminally advancing a therapeutic device to the site of the obstruction via the internal carotid artery ICA.
  • It is well known in the art to percutaneously and transluminally advance a catheter in retrograde fashion toward coronary vasculature, e.g., via the femoral artery, external iliac artery, descending aorta DA and aortic arch AA. To access cerebral vasculature, including obstructions residing in the MCA, one approach is to further advance a catheter and/or therapeutic devices in antegrade fashion from the aortic arch AA, into the common carotid artery CCA, up through the ICA and into the middle cerebral artery MCA, as shown in FIG. 1.
  • Treating occlusions in the MCA may generate emboli upon removal of the occlusion. Under normal blood flow conditions, such emboli may travel downstream from the original occlusion and cause ischemia. Accordingly, it is advantageous to manipulate blood flow characteristics in the cerebral vasculature to ensure that emboli generated in the MCA are effectively removed.
  • The present invention manipulates cerebral blood flow by inhibiting flow from the heart into any of the vertebral arteries VA and common carotid arteries CCA. This may be achieved by disposing flow control devices in the subclavian arteries SA and/or brachiocephalic trunk BT, to temporarily inhibit flow from the aortic arch AA into any of the vertebral arteries VA and common carotid arteries CCA. This interruption of antegrade flow may advantageously alter flow in the Circle of Willis, as described hereinbelow.
  • FIG. 2 provides an overview of the components of the system of the present invention, each of which are described in greater detail hereinbelow.
  • Flow control devices 8 having occlusive elements 6 are configured to be introduced into the patient's vasculature, e.g., via the radial or brachial arteries. When so positioned, occlusive elements 6 preferably are positioned in the patient's left subclavian artery SA and brachiocephalic trunk BT, as shown. Occlusive elements 6 may have any of a number of designs, with low profile mechanically self-expanding designs being preferred.
  • Emboli removal catheter 2 includes distal occlusive element 4, and is configured to be percutaneously advanced in retrograde fashion through the descending aorta. Occlusive element 4 preferably comprises a pear-shaped or funnel-shaped balloon as described in copending and commonly assigned U.S. patent application Ser. No. 09/418,727, which is incorporated herein by reference. Occlusive element 4 preferably is positioned proximal to the carotid bifurcation, and then deployed to induce retrograde flow in the ICA by use of a venous return catheter (not shown) that communicates with the proximal end of catheter 2. Balloon 10, also described in the foregoing application, is deployed in the ECA to ensure that retrograde flow from the ICA is not carried in an antegrade fashion into the ECA.
  • Flow control devices 8 and emboli removal catheter 2 are used to suspend antegrade flow in the cerebral arteries and to selectively suspend or redistribute flow in the cerebral vasculature. Once so-deployed, a lysing agent may be introduced to dissolve the clot, followed by selectively contracting one or more of the flow control devices to induce retrograde flow through emboli removal catheter 2.
  • Alternatively, after placement of flow control devices 8, but before they are deployed, thrombectomy wire 12 may be introduced into the vessel containing the lesion. Flow control devices 8 then may be deployed, as shown in FIG. 2, to prevent flow from the aortic arch AA into the right common carotid artery RCCA and the right and left vertebral arteries VA. Such selective manipulation of flow into the carotid and/or vertebral arteries alters flow characteristics in the cerebral vasculature, and permits retrograde flow through to be induced to flush emboli and debris into the lumen of catheter 2 for removal.
  • In the embodiment of FIG. 2, thrombectomy wire 12 comprises knot 14 that is deployed distal to the thrombus T. Thrombectomy wire 12 and thrombus T then are retracted proximally into the lumen of emboli removal catheter 2, and any embolic fragments generated during this procedure are directed into catheter 2 by inducing localized retrograde flow. Once the thrombus is removed, flow control devices 8 are contracted to reestablish flow to the cerebral vasculature.
  • Referring now to FIG. 3A, stroke treatment apparatus 40 constructed in accordance with the principles of the present invention is described. Apparatus 40 comprises emboli removal catheter 41, wire 45, venous return line 52, tubing 49 and optional blood filter 50.
  • Catheter 41 includes distal occlusive element 42, hemostatic ports 43 a and 43 b, e.g., Touhy-Borst connectors, inflation port 44, and blood outlet port 48. Wire 45 includes balloon 46 that is inflated via inflation port 47. Tubing 49 couples blood outlet port 48 to filter 50 and blood inlet port 51 of venous return line 52.
  • Wire 45 preferably comprises a small diameter flexible shaft having an inflation lumen that couples inflatable balloon 46 to inflation port 47. Wire 45 and balloon 46 are configured to pass through hemostatic ports 43 a and 43 b and the aspiration lumen of catheter 41 (see FIGS. 3C and 3D), so that balloon 46 may be disposed in a communicating artery, e.g., the external carotid artery. Ports 43 a and 43 b and the aspiration lumen of catheter 41 are sized to permit additional interventional devices, such as thrombectomy wires, to be advanced through the aspiration lumen when wire 45 is deployed.
  • Venous return line 52 includes hemostatic port 53, blood inlet port 51 and a lumen that communicates with ports 53 and 51 and tip 54. Venous return line 52 may be constructed in a manner per se known for venous introducer catheters. Tubing 49 may comprise a suitable length of a biocompatible material, such as silicone. Alternatively, tubing 49 may be omitted and blood outlet port 48 of catheter 41 and blood inlet port 51 of venous return line 52 may be lengthened to engage either end of filter 50 or each other.
  • With respect to FIGS. 3B and 3C, distal occlusive element 42 comprises expandable funnel-shaped balloon 55. In accordance with manufacturing techniques which are known in the art, balloon 55 comprises a compliant material, such as polyurethane, latex or polyisoprene which has variable thickness along its length to provide a funnel shape when inflated. Balloon 55 is affixed to distal end 56 of catheter 41 in an inverted fashion, for example, by gluing or a melt-bond, so that opening 57 in balloon 55 leads into aspiration lumen 58 of catheter 41. Balloon 55 preferably is wrapped and heat treated during manufacture so that distal portion 59 of the balloon extends beyond the distal end of catheter 41 and provides an atraumatic tip or bumper for the catheter.
  • As shown in FIG. 3D, catheter 41 preferably comprises inner layer 60 of low-friction material, such as polytetrafluoroethylene (“PTFE”), covered with a layer of flat stainless steel wire braid 61 and polymer cover 62 (e.g., polyurethane, polyethylene, or PEBAX). Inflation lumen 63 is disposed within polymer cover 62 and couples inflation port 44 to balloon 55.
  • Referring to FIGS. 4, features of the flow control devices of the present invention are described. The flow control devices may comprise either an inflatable balloon or a mechanically deployable mechanism. In FIG. 4A, a preferred embodiment of the proximal end for a mechanically deployable mechanism comprises controller 70, delivery port 78, e.g., for delivering cardioplegic agents, deployment knob 72 that is configured to slide within slot 74, and guidewire lumen 76, which may comprise a self-sealing valve. Body 73 houses a plurality of lumens, e.g., a mechanical deployment lumen, a therapeutic drug delivery lumen, and a guidewire lumen. In an alternative embodiment, for use in conjunction with an inflatable balloon, port 78 may serve as an inflation/aspiration port while deployment knob 72 and slot 74 are omitted.
  • FIGS. 4B-4C illustrate the distal end of the flow control device having inflatable balloon 82 in contracted and deployed states, respectively. In use, body 73 is advanced over a guidewire via guidewire lumen 86. Radiopaque tip marker 84 may be used to aid in fluoroscopically guiding the device. Balloon 82 then is inflated by a lumen within body 73 that communicates with port 78. Port 78 may communicate with a timing mechanism (not shown) that automatically deflates balloon 82 after a predetermined time, e.g., 15 seconds, to ensure that cerebral blood flow is not inhibited for a period so long as to cause cerebral compromise.
  • FIGS. 4D-4E illustrate mechanically deployable mechanism 92 comprising flexible wires 95 and impermeable coating 97 in contracted and deployed states, respectively. Impermeable coating 97 comprises an elastomeric polymer, e.g., latex, polyurethane or polyisoprene. The proximal end of deployable mechanism 92 is affixed to body 73. The distal end of mechanism 92 is affixed to distalmost section 99, which in turn communicates with sliding member 93 that is configured to slide longitudinally within a lumen of body 73.
  • Upon actuating deployment knob 72, i.e., proximally retracting knob 72 within slot 74, sliding member 93 and distalmost section 99 are proximally retracted relative to body 73, to compress flexible wires 95. Impermeable coating 97 conforms to the shape of wires 95 to provide a plug-shaped occlusive member, as shown in FIG. 4E. Deployment knob 72 may communicate with a timing mechanism (not shown) that automatically releases mechanism 92 after a predetermined time.
  • Referring to FIGS. 5, alternative embodiments for guide wire 45 and balloon 46 of FIG. 3A are described for use in occluding a communicating artery, e.g., the external carotid artery. In FIG. 5A, occlusive device 121 comprises proximal hub 120, hypo tube 127, shaft 128, balloon 136 and coil 142. Hypo tube 127 preferably comprises stainless steel, while shaft 128 preferably comprises a radiopaque material. Balloon 136 is configured using a tubular balloon material, e.g., chronoprene, that is compliant in nature and provides a self-centering balloon when deployed. The proximal end of balloon 136 is secured to radiopaque shaft 128 by band 132 and taper 130. The distal end of balloon 136 is affixed to coil 142 via taper 140.
  • Core wire 122 is slidably disposed within hypo tube 127 so that its proximal end and is disposed in proximal hub 120 and its distal end is affixed to taper 140. Fluid may be injected into the annulus surrounding core wire 122 so that the fluid exits into balloon 136 via inflation window 134, thus permitting balloon 136 to expand radially and longitudinally. Core wire 122, taper 140 and coil 142 may move distally to accommodate such linear extension. Stroke limiter 123, disposed on the distal end of core wire 122, ensures that balloon 136 does not extend longitudinally more a predetermined distance ‘x’.
  • In the alternative embodiment of FIG. 5B, occlusive device 151 comprises shaft 152, balloon 158, and coil 168. Shaft 152 preferably comprises a radiopaque material and connects to a hypo tube similar to that of FIG. 5A. The proximal components for device 151, i.e., proximal to shaft 152, are the same as the components that are proximal to shaft 128 in FIG. 5A.
  • Balloon 158 is constrained at its proximal end by band 156 having proximal balloon-marker 157. Taper 154 is provided on the proximal end of band 156 in alignment with the proximal end of balloon 158. The distal end of balloon 158 is everted, as shown in FIG. 5B, and secured with radiopaque band 160 that provides a fluoroscopic reference for the distal boundary of the balloon. Taper 164 further secures the everted distal section, sandwiching between the first and second folds.
  • Core wire 150 is distally affixed to coil 168 having radiopaque marker 170. Lumen 159 communicates with an inflation port (not shown) at its proximal end and with inflation window 136 at its distal end. Lumen 159 permits the injection of fluids, e.g., saline, to deploy balloon 158. Core wire 150 is slidably disposed in the hypo tube and shaft 152 to prevent extension of balloon 158 up to a distance ‘x’, as indicated in FIG. 5A.
  • Referring to FIGS. 6, apparatus suitable for removing thrombi are described. In FIG. 6A, thrombectomy wire 200 having ball 202 affixed to its distal end is depicted in a contracted state within coil 204. In a preferred embodiment, thrombectomy wire 200 comprises a shape-memory retaining material, for example, a Nickel Titanium alloy (commonly known in the art as Nitinol).
  • The use of Nitinol generally requires the setting of a custom shape in a piece of Nitinol, e.g., by constraining the Nitinol element on a mandrel or fixture in the desired shape, and then applying an appropriate heat treatments, which are per se known.
  • Coil 204 covers wire 202 along its length, up to ball 202. As coil 204 is retracted proximally, wire 200 self-expands to a predetermined knot configuration, as. shown in FIG. 6B. In a preferred embodiment, the diameter of wire 200 is about 0.002 inches, the diameter of ball 202 is about 0.014 inches, and coil 204 is manufactured using platinum. It should be appreciated that an outer sheath may be used in place o˜ coil 204, such that proximally retracting the outer sheath causes wire 200 to deploy.
  • Referring to FIG. 6C, a method for using thrombectomy wire 200 to snare a thrombus T, e.g., in middle cerebral artery MCA, is described. Thrombectomy wire 200, initially contracted within coil 204, is advanced through a lumen of catheter 2, then preferably is advanced in retrograde fashion via the internal carotid to the site of the cerebral lesion in the MCA. Under controlled flow conditions, i.e., conditions that will promote the flow of emboli toward catheter 2, wire 200 and coil 204 pierce thrombus T, as shown in FIG. 6C.
  • Coil 204 then is retracted proximally with respect to wire 200 to self-deploy shape memory wire 200 at a location distal to thrombus T, as shown in FIG. 6D. Wire 200 then is retracted to snare thrombus T, and ball 202 of wire 200 facilitates removal of the lesion.
  • Referring to FIGS. 6E-6F, an alternative embodiment a thrombectomy wire of FIGS. 6A-B is described. In FIG. 6E, thrombectomy wire 205 having distal ball 208 is delivered in a contracted state within slidable sheath 206. Thrombectomy wire 205 is configured to self-deploy to a predetermined shape, e.g., via use of a shape memory material, upon proximal retraction of sheath 206. Coil 207 overlays slidable sheath 206 and is. affixed to ball 208 at points 209 a and 209 b, e.g., via a solder or weld. Sheath 206 is initially provided in a distalmost position such that it abuts ball 208 and constrains wire 205 along its length. Sheath 206 advantageously enhances the distal pushability of the device, particularly when the device is advanced though an occlusion.
  • Upon positioning the distal end of wire 205 at a location distal to the occlusion, sheath 206 is retracted proximally to cause wire 205 to self-deploy to a knot-shaped configuration, as depicted in FIG. 6F. Coil 207, affixed to ball 208 of wire 205, conforms to the shape of wire 205. The deployed knot-shaped device then is proximally retracted to snare the occlusion, according to methods described hereinabove.
  • Referring to FIGS. 7A-7E, alternative embodiments for thrombectomy wires in accordance with the present invention are depicted. In FIG. 7A, thrombectomy wire 210 comprises a plurality of intersecting ˜oops that deploy upon retraction of a coil or sheath. Hoops 212 and 214 may be orthogonal to each other, as shown in FIG. 7A. The hoops are designed to form a knot-shape to snare a thrombus in combination with ball 216. Additionally, there may be a series of intersecting hoops, as shown in FIG. 7B. Thrombectomy wire 220 comprises first knot 222 and second knot 224 separated by a distance ‘y’, although it will be obvious that any variation in the number of knots and their shapes are intended to fall within the scope of the present invention.
  • Referring to FIG. 7C, thrombectomy wire 230 comprises spiral-shaped distal section 232. The spiral shape is formed from a series of planar hoops, the diameter of hoops being slightly smaller with each successive hoop. As shown, the hoops of spiral 232 are depicted as being orthogonal to the main axis of wire 230. Elbow 234 defines a bent section that connects main wire section 236 to first hoop 238. As shown, elbow 234 is orthogonal to main wire section 236, however, it may be provided at any angle. Similarly, as shown in FIG. 7D, wire 240 may comprise a plurality of spiral-shaped sections 242 and 244 separated by a distance ‘z’.
  • In FIG. 7E, thrombectomy wire 250 comprise a plurality of petal-shaped sections that deploy upon retraction of a coil or sheath. As shown, petal-shaped sections 252 and 254 are orthogonal to each other, however, they may be provided at any angle with respect to main axis 256 and each other, and any number of petal-shaped sections may be provided.
  • Referring to FIGS. 8A-8D, a further alternative thrombectomy device is illustrated. Device 260 removes a lesion by organizing the fibrin strands of the lesion around the deployable wires using a rotational motion. Exemplary method steps for using the embodiments described in FIGS. 8A-8D are described in FIGS. 10 hereinbelow.
  • In FIG. 8A, thrombectomy device 260 comprises at least one deployable wire 262 affixed at its proximal and distal ends at points 266 and 264, respectively. Deployable wire 262 is initially contracted within coil 268, and when tubular member 268, e.g., a coil or sheath, is retracted proximally, deployable wires 262 self-expand to a predetermined shape, as shown. As deployable wires 262 are rotated within the thrombus itself, the fibrin strands of the thrombus will become engaged with and wrap around deployable wires 262.
  • In FIG. 8B, alternative thrombectomy device 270 comprises at least one deployable wire 274 that is distally affixed to wire 270 at point 276. The proximal end of wire 274 is secured to sliding member 272, which slides longitudinally over wire 271. When wire 271 and sliding member 272 move with respect to each other, deployable wire 274 either radially outwardly deflects, as shown, or flattens out for a contracted position.
  • In FIG. 8C, thrombectomy device 280 comprises deployable wire 282 configured to form a plurality of loops 285 around shaft 283. The distal end of deployable wire 282 is affixed to shaft 283 at point 284, which may serve as an atraumatic tip for guiding the device and piercing the thrombus. The proximal end of deployable wire 282 is affixed to tube 281. Tube 281 spans the length of the device and has a proximal end that is manipulated by the physician. Distally advancing tube 281 over shaft 283 deploys loops 285, as shown, while proximally retracting tube 281 with respect to shaft 283 contracts loops 285. In the deployed state, rotating the device about its axis will cause loops 285 of wire 282 to engage the thrombus and wrap the fibrin strands about the device, as described in FIGS. 10 hereinbelow.
  • In FIG. 8D, thrombectomy device 290 comprises a plurality of shape-memory, arrowhead-shaped wires 292 that are distally affixed to each other at point 294 and proximally affixed at junction 298. Wires 292 are initially contracted within tubular member 296, e.g., a coil or sheath, and upon proximal retraction of tubular member 296, wires 292 self-deploy to the configuration shown.
  • Apparatus and methods for organizing fibrin strands of a thrombus around a thrombectomy device are further described with respect to FIGS. 9 and 10. In FIG. 9A, thrombectomy device, 300 comprises proximal segment 306, catheter 302, and distal segment 304. Proximal segment 306 comprises thumb ring 308, proximal body 310, and deployment knob 312 that slides longitudinally within slot 314. Distal segment 304 comprises at least one deployable wire 316 and atraumatic tip 318.
  • FIG. 9B provides a schematic view of distal segment 304. Deployable wire 316 preferably comprises a shape memory material that communicates with deployment knob 312 at its proximal end, as described in FIG. 9C hereinbelow. The distal end of deployable wire 316 is affixed to atraumatic tip 318, e.g., using a solder or weld. Deployable wire 316 is delivered in a contracted state, i.e., such that it does not substantially extend radially beyond catheter. 302. Upon actuation of deployment knob 312, wire 316 self-expands via holes 317 to form a whisk-type element, as shown. Catheter 302 may be provided with one or more working lumens that. communicate with delivery port 305 to permit the delivery of fluids, e.g., saline or other drugs that facilitate clot removal.
  • FIG. 9C provides a schematic view of proximal segment 306. The distal end of deployable wire 316 is configured to deploy from catheter 302. The proximal end of catheter 302 is affixed to outer shaft 322, which preferably has a square cross-section. Outer shaft 322 is keyed to inner shaft 320. Inner shaft 320 is keyed to slidably more actuator 323, so that rotational motion of one element causes rotation of the other. Catheter 302 further is affixed to retainer 315, which permits catheter 302 to rotate freely relative to proximal body 310.
  • Thumb ring 308 communicates with actuator 323 via joint 321. Joint 321 permits rotational motion of actuator 323 with respect to thumb ring 308. Actuator 323 is affixed to rotational member 326 at its distal end, which in turn is affixed to inner shaft 320. Rotational member 326 comprises knob 327 that is configured to slidably rotate within groove 328 in the wall of body 310.
  • Deployable wire 316 is deployed by sliding deployment knob 312 within slot 314. Deployment knob 312 comprises a rounded pin that engages with a groove of ring 324. This engagement distally advances ring 324 within slot 325 of catheter 302. Deployable wire 316 is affixed to ring 324, such that distally advancing ring 324 via deployment knob 312 allows wire 316 to self-deploy. The rounded pin engagement between knob” 312 and the groove of ring 324 further permits free axial rotation of ring 324 while knob 312 is stationary.
  • With wire 316 deployed, thumb-ring 308 is depressed with a force that overcomes a resistance force provided by spring 330. Depressing thumb ring 308 in turn causes rotational member 326 to be advanced distally via groove 328. When a thumb force is no longer applied, the resistance of spring 330 then pushes rotating member 326 in a proximal direction via groove 328. This in turn causes rotation of rotational member 326, inner shaft 320, outer shaft 322 and catheter 302. The rotation of catheter 302 generates rotation of thrombectomy wire 316.
  • The rotation of thrombectomy wire 316 may be clockwise, counterclockwise, or a combination thereof by manipulating the profile of groove 328. The rotational speed may be controlled by varying the resistance of spring 330, and the duration of rotation can be controlled by varying the length in which rotational member 326 can longitudinally move. Alternatively, another force transmission means, e.g., a motor, may be coupled to the proximal end to provide for controlled axial rotation of catheter 302.
  • FIGS. 10 illustrate method steps for removing thrombi using any of the thrombectomy devices described in FIGS. 8-9. In a first step, catheter 302 is advanced through catheter 2 of FIG. 2, then advanced in a retrograde fashion toward the occlusion. Catheter 302 may be advanced via the internal carotid artery to treat a lesion T located in a cerebral vessel V, e.g., the middle cerebral artery. Atraumatic tip 318 serves to protect vessel walls as catheter 302 is advanced through tortuous anatomy. At this time, flow control devices 8 of FIG. 2 are deployed to cause retrograde blood to flow in the directions indicated.
  • Tip 318 of catheter 302 then is advanced to pierce thrombus T, as shown in FIG. 10B. Deployment knob 312 of FIG. 9 then is actuated to deploy at least one deployable wire 316 within thrombus T. Thumb ring 308 then is depressed, resulting in the controlled rotation of deployable wire 316, such that the wire engages the fibrin strands of thrombus T. As the fibrin strands are wound about deployable wire 316, the diameter of thrombus T decreases, as shown in FIG. 10D. Blood flows in a retrograde fashion, i.e., toward catheter 2 which is positioned in the common carotid artery, and any emboli E generated during the procedure will be removed by the catheter in the process. It should be noted that deployable wire 316 is designed such that it does not contact the inner wall of vessel V. Once the thrombus T is sufficiently wound about deployable wire 316, as shown in FIG. 1E, catheter 302 may be retracted into catheter 2.
  • Referring to FIG. 11, an alternative embodiment of the present invention is described wherein a second catheter is advanced to a location in closer proximity to the occlusive lesion. Main catheter 340 having distal occlusive element 342 is positioned, for example, in the common carotid artery, as described in FIG. 2. Recovery catheter 344 having distal occlusive element 346 and radiopaque marker 347 is configured to telescope within the lumen of main catheter 340.
  • In a preferred method, main catheter 340 is disposed in the common carotid artery. Retrograde flow then is established using venous return line 52 of FIG. 3A according to methods described hereinabove. A 0.014 inch neuro guidewire 350 then is advanced via the lumen of main catheter 340 to the site of the cerebral occlusion, and neuro guidewire 350 is disposed distal to the lesion. In this illustration, an occlusion (not shown) would be located approximately within an interval ‘L’, e.g., in the middle cerebral artery. Recovery catheter 344 then is advanced distally over neuro guidewire 350 and is positioned proximal to occlusion ‘L’. Upon positioning recovery catheter 344, occlusive distal element 346 is deployed.
  • Neuro catheter 348 then is advanced over neuro guidewire 350, and the distal end of neuro catheter 348 is disposed at a location distal to occlusion ‘L’, as shown. Neuro guidewire 350 then is retracted proximally and removed from within neuro catheter 348, which comprises a relatively small lumen. With neuro guidewire 350 removed, a thrombectomy wire is advanced distally through the lumen of neuro catheter 348, and the thrombectomy wire takes the place of guidewire 350 in FIG. 11. Neuro catheter 348 then is proximally retracted, and thrombectomy wire 350 is deployed to treat the occlusion according to methods described hereinabove.
  • Recovery catheter 344 comprises at least one blood venting hole 345. The established retrograde flow through catheter 344 using venous return line 52 induces retrograde flow in at least the internal carotid artery via blood venting hole 345. Flow into venting hole 345 may be manipulated by actuating inner sheath 349, e.g., by longitudinally sliding inner sheath 349 within catheter 344, or rotating inner sheath 349 relative to its longitudinal axis.
  • Advantageously, the distal end of recovery catheter 344 is positioned in close proximity to the lesion, so that wire 348 and any emboli generated are immediately confined within recovery catheter 344. Furthermore, advancing recovery catheter 344 via the internal carotid artery eliminates the need for deploying balloon 10 of FIG. 2 in the external carotid artery.
  • Referring to FIGS. 12, a further alternative embodiment of the present invention is described wherein a second catheter is advanced to a location in closer proximity to the occlusive lesion. Main catheter 360 having distal occlusive element 362 is positioned, for example, in the common carotid artery, as described in FIG. 2. Recovery catheter 364 comprises a wire weave configuration and may be manufactured using a shape memory material, e.g., Nitinol, as described hereinabove.
  • Recovery catheter 364 further comprises blood impermeable membrane 365, such as latex, polyurethane or polyisoprene, that encloses the wire weave of recovery catheter 364. The elastic properties of blood impermeable membrane 365 allow it to conform to the contracted and expanded states of recovery catheter 364.
  • Recovery catheter 364 is advanced in a contracted state within outer sheath 366. As described in applicants' commonly assigned, co-pending application Ser. No. 09/916,349, which is herein incorporated by reference, outer sheath 366 is retracted proximally to cause occlusive distal section 368 to self-expand to a predetermined deployed configuration, as shown in FIG. 12A. Occlusive distal section 368 may be sized for different vessels, e.g., the middle cerebral arteries, so that the distal end of recovery catheter 364 is disposed proximal to an occlusion, e.g., as depicted at location ‘L’. Mouth 369 provides a relatively large distal opening, i.e., flush with the inner wall of the targeted vessel.
  • Neuro catheter 370 then is advanced over neuro guidewire 372, as described hereinabove in FIG. 11, and a thrombectomy wire is exchanged for neuro guidewire 372. Neuro catheter 370 is proximally retracted, and thrombectomy wire 372 removes the occlusion at location ‘L’ according to methods described hereinabove. Upon removing the occlusion, thrombectomy wire 372 is retracted into mouth 369, along with any” emboli generated during the procedure.
  • It will be advantageous to collapse mouth 369 upon completion of the procedure, to prevent thrombi and/or emboli from exiting removal catheter 364. FIGS. 12B-12D illustrate a method for effectively collapsing mouth 369 proximally to distally, as shown. FIG. 12B shows outer sheath 366 having radiopaque marker 367 in a proximally retracted position that allows occlusive distal section 368 to deploy. After directing thrombi and/or emboli into mouth 369, outer sheath 366 is advanced distally to collapse mouth 369, as shown sequentially in FIGS. 12C-12D. This effectively confines thrombi and/or emboli within mouth 369.
  • Referring now to FIGS. 13, a method for using the apparatus described hereinabove to treat stroke, in accordance with principles of the present invention, is described. In FIG. 13A, flow control devices 400 having controllers 402 are introduced into the patient's vasculature in a contracted state, e.g., via the radial or brachial arteries, and preferably are positioned in the patient's left subclavian artery and brachiocephalic trunk, as shown. It will be appreciated by those skilled in the art that varying the number of flow control devices and their placements is intended to fall within the scope of the present invention. Blood flow occurs in the directions indicated.
  • Referring to FIG. 13B, catheter 404 of FIG. 3A is positioned in the common carotid artery CCA using guide wire 406. Catheter 404 is positioned proximal to the carotid bifurcation, as shown, preferably in the hemisphere in which the cerebral occlusion is located. Balloon 408, for example, as described in FIGS. 5, then is disposed in the external carotid artery and deployed, as shown in FIG. 13C.
  • Referring to FIG. 13D, distal occlusive element 412 of catheter 404 is deployed to occlude ante grade flow in the selected CCA. Venous return catheter 52 of FIG. 3A then is placed in a remote vein, such that negative pressure in venous return catheter 52 during diastole establishes a continuous flow through the lumen of catheter 404. This induces retrograde flow in the ICA, as depicted in FIG. 13D. A thrombectomy wire 414, for example, as described in FIGS. 6-10, is advanced through catheter 404 and into the cerebral vasculature via the ICA.
  • Referring to FIG. 13E, a view of the cerebral vasculature under the conditions described in FIG. 13D is shown. Thrombectomy wire 414 has been advanced to a location just proximal to thrombus T, for example, in middle cerebral artery MCA.
  • At this time, flow control devices 400 then are deployed using controller 402 to form occlusive elements 420, as shown in FIG. 13F. As depicted, flow from aortic arch AA into brachiocephalic trunk BT and left subclavian artery SA are inhibited, which in turn inhibits flow into the vertebral arteries VA and right CCA, as shown. It will be apparent to those skilled in the art that occlusive elements 420 may be selectively placed at other locations to permit and/or inhibit flow into the selected locations of the cerebral vasculature.
  • The deployment of occlusive elements 420 controls flow in the Circle of Willis, as shown in FIG. 13G. In this example, since arterial flow into the vertebral arteries VA and the right internal carotid artery has been inhibited, emboli that are generated will be directed in a retrograde fashion toward catheter 404 the left internal carotid artery. The distal end of thrombectomy wire 414 then pierces thrombus T and deployable knot 416 is deployed distal to the thrombus, as shown in FIG. 13G. Alternatively, other thrombectomy wire configurations may be used to treat the lesion, as described in FIGS. 6-10.
  • Deployable knot 416 of thrombectomy wire 414 snares thrombus T, as shown in FIG. 13H, and subsequently is retracted into catheter 404. Any emboli generated during the procedure will be directed into catheter 404 via the established retrograde flow. Occlusive elements 420, distal occlusive element 412, and external carotid occlusive device 408 then are contracted, and catheter 404 may be removed from the patient.
  • It should be noted that the method steps described in FIGS. 13 may be used in combination with any of the apparatus described hereinabove. For example, recovery catheters 344 and 364 of FIGS. 11 and 12, respectively, may be advanced through catheter 404 of FIGS. 13. Additionally, any of the snaring thrombectomy devices of FIGS. 7 or the rotating thrombectomy devices of FIGS. 8 may be used in place of thrombectomy wire 414 as depicted. Similarly, any of the occlusive devices described in FIGS. 4B-4E and FIGS. 5A-5B may be used in place of occlusive elements 420 and 408, respectively.
  • Referring to FIGS. 14-16, further apparatus and methods is accordance with principles of the present are described. In FIG. 14A, catheter 430 may be configured for use in any of the carotid and vertebral arteries. Catheter 430 comprises blood intake port 432, distal occlusive element 436 and radiopaque tip marker 435. Occlusive element 436 comprises proximal and distal tapers 438 and 440, respectively. Inner sheath 434 is configured for longitudinal sliding motion within catheter 430.
  • Inner sheath 434 is initially provided in a distalmost position that covers blood intake port 432 in a closed state, as shown in FIG. 14A. Deployment of occlusive element 436 inhibits antegrade blood flow in vessel V, at which time therapeutic drugs and/or devices may be delivered to site of the occlusion via lumen 437.
  • Retrograde blood flow in vessel V is induced by placing venous return catheter 52 of FIG. 3A into a remote vein, according to methods described hereinabove. The retrograde flow through lumen 437 induces retrograde flow distal to occlusive element 436. Distal taper 440 facilitates retrograde blood flow into lumen 437.
  • If antegrade flow is desired, inner sheath 434 may be retracted proximally to expose blood intake port 432, as shown in FIG. 14B. This permits antegrade flow to enter intake port 432 and continue flowing in an antegrade direction distal to occlusive element 436. Proximal taper 438 is configured to enhance antegrade blood flow into intake port 432.
  • Cerebral flow manipulation may be enhanced by placing a first catheter in accordance with FIGS. 14 in a common carotid artery and a second catheter in a vertebral artery, each on the hemisphere of the occlusion. FIG. 15 depicts apparatus suitable for controlling cerebral flow when utilizing one carotid and one vertebral catheter in combination. In FIG. 15, catheters 450 and 470 are configured to be disposed in the common carotid and vertebral arteries, respectively. However, it should be appreciated by those skilled in the art that two vertebral catheters may be used, i.e., one in each of the vertebral arteries, in combination with the carotid catheter.
  • Catheters 450 and 470 each comprises a plurality of lumens. Inner sheaths 456 and 476 are configured to slide longitudinally within an outermost lumen of their respective catheters. Inner sheaths 456 and 476 communicate with deployment knobs 452 and 472. Sliding deployment knobs 452 and 472 within slots 454 and 474 controls movement of inner sheaths 456 and 476, respectively.
  • Inflation ports 462 and 482 communicate with lumens of their respective catheters. Working lumens 458, 460, 478 and 480 provide each catheter with two working lumens, e.g., for advancing guide wires and thrombectomy wires, and may be provided with hemostatic valves, for example, Touhy-Borst connectors.
  • Biocompatible tubing 459 and 461 enable fluid communication between retrograde flow controller 465 and lumens of catheter 450 and 470, respectively. Retrograde flow controller 465 further communicates with venous return line 52 of FIG. 3A via tubing 463. Switch 467 of retrograde flow controller 465 permits tubing 459 and 461 to communicate with retrograde flow of tubing 463 singularly or in combination, or switch 467 may inhibit retrograde flow altogether. For example, when retrograde flow is induced in tubing 463 via venous return line 52, either one of tubing 459 and 461, both, or neither may experience retrograde flow based on the position of switch 467.
  • The apparatus described in FIG. 15 allow a physician to provide either retrograde, antegrade or hemostatic flow from two opposing cerebral locations, i.e., the carotid and vertebral arteries. The lumens of the vertebral and/or carotid catheters may be perfused with blood or saline under pressure to manipulate flow at selected cerebral locations. The apparatus further allows for the injection of therapeutic drugs and/or thrombectomy devices. Chilled blood or saline may be delivered via either of the carotid and vertebral catheters to induce mild hypothermia at selected cerebral locations, while drug agents may be used to selectively alter the pressure gradients.
  • Additionally, lytic agents may be delivered via either of the carotid or vertebral catheters to aid in the disintegration of the occlusion. Such lytic agents preferably are used in combination with the flow manipulation techniques in accordance with the present invention, to direct emboli resulting from the lytic process into the removal catheter(s).
  • Referring to FIGS. 16, method steps are described to manipulate cerebral flow in a variety of ways using a combination of carotid and vertebral catheters. In FIG. 16A, a first catheter 500 comprising occlusive element 502 and blood intake port 504 is disposed in the left common carotid artery CCA. Inner sheath 506 is provided in a distalmost position to prevent fluid from entering intake port 504, and occlusive element 502 is deployed to occlude antegrade flow. Balloon 508, e.g., as described in FIGS. 5, then is deployed in the ECA.
  • Similarly, a second catheter 520 comprising occlusive element 522 and blood intake port 524 is disposed in the left and/or right vertebral artery VA. In this example, one catheter is shown. Inner sheath 526 is provided in a distalmost position to prevent fluid from entering intake port 544, and occlusive element 522 is deployed to occlude antegrade flow.
  • Venous return line 52 of FIG. 3A then is placed in a remote vein, according to methods described hereinabove, and retrograde flow may be induced either in the ICA, VA, or both arteries based on switch 467 of FIG. 15. As depicted in FIG. 16A, switch 467 is set to a position that permits retrograde flow to be induced in both the carotid and vertebral catheters.
  • At this time, any of the flow control devices described in FIGS. 4 optionally may be deployed to occlude flow in the opposing carotid and vertebral arteries, according to methods described hereinabove. In this example, this ensures that blood flow is controlled in the left hemisphere.
  • The retrograde flow from catheters 500 and 520 encourages blood flowing in the middle cerebral artery MCA to flow toward both catheters, as indicated by the arrows in FIG. 16A. Thrombectomy wire 510 having deployable knot 512 then is advanced into the MCA via the ICA and snares thrombus T, according to methods described hereinabove. Emboli E generated during the procedure are directed toward either one of catheters 500 and 520 for removal. Advantageously, the use of two catheters in combination provides for improved aspiration of the targeted vessel, in this case, the MCA.
  • Referring to FIG. 16B, deployable knob 472 of FIG. 15 is proximally retracted to retract inner sheath 526 and expose intake port 524 of catheter 520. Switch 467 of retrograde flow controller 465 is positioned for retrograde flow only through catheter 500. This allows antegrade flow in vertebral artery VA to enter intake port 524 and continue flowing in an antegrade direction into basilar artery BA and toward the MCA via the path indicated. The combination of antegrade flow from the left VA and either antegrade or retrograde flow from the left ICA directs emboli E generated in the MCA to flow primarily into catheter 500.
  • There are several other variations possible for manipulating flow in the cerebral vasculature, to more efficiently deliver therapeutic drugs and/or direct emboli into a removal catheter. For example, therapeutic drugs may be delivered to the MCA when switch 467 of FIG. 15 inhibits venous flow into both catheters 500 and 520, and each of blood intake ports 504 and 524 are closed.
  • Therapeutic drugs may be delivered via either port 458 or 478 into the MCA, or mild hypothermia may be induced by introducing chilled blood or saline.
  • It should be appreciated that varying the settings of retrograde flow controller 465 and deployable knobs 452 and 472 may provide for any combination of antegrade, retrograde, or hemostatic flow in the carotid and vertebral arteries. There are too many flow combinations to illustrate, however, it is intended that therapeutic drugs, thrombectomy devices, cardioplegic and/or brain chilling agents may be delivered under a variety of controlled cerebral flow conditions. Additionally, a neuro guidewire and neuro catheter, as described in FIGS. 11 and 12A hereinabove, may be used in conjunction with thrombectomy wire 510 of FIGS. 16.
  • While preferred illustrative embodiments of the invention are described above, it will be apparent to one skilled in the art that various changes and modifications may be made therein without departing from the invention. The appended claims are intended to cover all such changes and modifications that fall within the true spirit and scope of the invention.

Claims (21)

1. Apparatus suitable for manipulating cerebral blood flow characteristics, the apparatus comprising:
a first catheter having proximal and distal ends, a lateral surface, and a lumen extending therebetween;
an occlusive element affixed to the distal end of the first catheter;
at least one intake port disposed in the lateral surface of the first catheter; and
an inner sheath configured for longitudinal sliding motion within the first catheter, the inner sheath configured to cover the intake port in a distalmost position.
2. The apparatus of claim 1 wherein the distal end of the first catheter is adapted to be disposed in a common carotid artery.
3. The apparatus of claim 1 further comprising a venous return catheter configured to induce retrograde flow through the lumen of the first catheter.
4. The apparatus of claim 3 further comprising a flow controller, the flow controller configured to selectively permit or inhibit communication between the venous return catheter and the lumen of the first catheter.
5. The apparatus of claim 1 further comprising:
a second catheter having proximal and distal ends, a lateral surface, and a lumen extending therebetween;
an occlusive element affixed to the distal end of the second catheter;
at least one intake port disposed in the lateral surface of the second catheter; and
an inner sheath configured for longitudinal sliding motion within the second catheter, the inner sheath configured to cover the intake port in a distalmost position.
6. The apparatus of claim 5 wherein the distal end of the second catheter is adapted to be disposed in a vertebral artery.
7. The apparatus of claim 5 further comprising a venous return catheter configured to induce retrograde flow through each of the lumens of the first and second catheters.
8. The apparatus of claim 7 further comprising a flow controller, the flow controller configured to selectively permit or inhibit communication between the venous return catheter and each of the lumens of the first and second catheters.
9. The apparatus of claim 1 wherein the occlusive element is a balloon.
10. The apparatus of claim 9 wherein the balloon comprises a proximal taper configured to channel antegrade flow into the intake port.
11. The apparatus of claim 10 wherein the balloon comprises a distal taper configured to channel retrograde flow into the lumen of the catheter.
12. The apparatus of claim 1 wherein proximally retracting the inner sheath exposes the intake port to cause antegrade blood to flow into intake port.
13. A method for manipulating cerebral blood flow characteristics, the method comprising:
providing apparatus comprising a first catheter having proximal and distal ends, a lateral surface, a lumen extending therebetween, an occlusive element affixed to the distal end of the first catheter, at least one intake port disposed in the lateral surface of the first catheter, and an inner sheath configured for longitudinal sliding motion within the first catheter;
positioning the distal end of the first catheter in a selected vessel in a contracted state; and
deploying the occlusive element to occlude antegrade flow in the selected vessel.
14. The method of claim 13 wherein the selected vessel is a common carotid artery.
15. The method of claim 13 further comprising: providing apparatus comprising a second catheter having proximal and distal ends, a lateral surface, a lumen extending therebetween, an occlusive element affixed to the distal end of the second catheter, at least one intake port disposed in the lateral surface of the second catheter, and an inner sheath configured for longitudinal sliding motion within the second catheter;
positioning the distal end of the second catheter in a selected vessel in a contracted state; and
deploying the occlusive element to occlude antegrade flow in the selected vessel.
16. The method of claim 15 wherein the selected vessel is a vertebral artery.
17. The method of claim 13 wherein proximally retracting the inner sheath exposes the intake port to permit antegrade flow to enter the lumen of the first catheter.
18. The method of claim 17 wherein exposing the intake port provides antegrade flow to selected regions of the cerebral vasculature.
19. The method of claim 13 further comprising:
providing a venous return catheter that communicates with the lumen of the first catheter; and
inducing retrograde flow through the lumen of the first catheter.
20. The method of claim 19 wherein inducing retrograde flow through the lumen of the first catheter induces retrograde flow at selected locations in the cerebral vasculature.
21. The method of claim 19 further comprising: providing a retrograde flow controller; and utilizing the retrograde flow controller to selectively permit or inhibit communication between the venous return catheter and the lumen of the first catheter.
US11/146,636 2001-08-22 2005-06-06 Apparatus and methods for treating stroke and controlling cerebral flow characteristics Abandoned US20050267323A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US11/146,636 US20050267323A1 (en) 2001-08-22 2005-06-06 Apparatus and methods for treating stroke and controlling cerebral flow characteristics

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US31426901P 2001-08-22 2001-08-22
US09/972,231 US6902540B2 (en) 2001-08-22 2001-10-04 Apparatus and methods for treating stroke and controlling cerebral flow characteristics
US11/146,636 US20050267323A1 (en) 2001-08-22 2005-06-06 Apparatus and methods for treating stroke and controlling cerebral flow characteristics

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US09/972,231 Division US6902540B2 (en) 2001-08-22 2001-10-04 Apparatus and methods for treating stroke and controlling cerebral flow characteristics

Publications (1)

Publication Number Publication Date
US20050267323A1 true US20050267323A1 (en) 2005-12-01

Family

ID=26979287

Family Applications (2)

Application Number Title Priority Date Filing Date
US09/972,231 Expired - Lifetime US6902540B2 (en) 2001-08-22 2001-10-04 Apparatus and methods for treating stroke and controlling cerebral flow characteristics
US11/146,636 Abandoned US20050267323A1 (en) 2001-08-22 2005-06-06 Apparatus and methods for treating stroke and controlling cerebral flow characteristics

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US09/972,231 Expired - Lifetime US6902540B2 (en) 2001-08-22 2001-10-04 Apparatus and methods for treating stroke and controlling cerebral flow characteristics

Country Status (1)

Country Link
US (2) US6902540B2 (en)

Cited By (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030183235A1 (en) * 2001-10-25 2003-10-02 Spiration, Inc. Bronchial obstruction device deployment system and method
US20050282444A1 (en) * 2004-06-17 2005-12-22 Irish Kenneth G Self-locking wire terminal and shape memory wire termination system
US20090198172A1 (en) * 2008-02-05 2009-08-06 Garrison Michi E Interventional sheath with retention features
US20100016832A1 (en) * 2008-07-17 2010-01-21 Tyco Healthcare Group Lp Spirally conformable infusion catheter
US7842061B2 (en) 2002-05-17 2010-11-30 Spiration, Inc. Methods of achieving lung volume reduction with removable anchored devices
US7942931B2 (en) 2002-02-21 2011-05-17 Spiration, Inc. Device and method for intra-bronchial provision of a therapeutic agent
US7998104B2 (en) 2003-11-21 2011-08-16 Silk Road Medical, Inc. Method and apparatus for treating a carotid artery
US20110213403A1 (en) * 2010-02-23 2011-09-01 Maria Aboytes Devices and methods for vascular recanalization
US8021385B2 (en) 2002-03-20 2011-09-20 Spiration, Inc. Removable anchored lung volume reduction devices and methods
US8043301B2 (en) 2007-10-12 2011-10-25 Spiration, Inc. Valve loader method, system, and apparatus
US8079368B2 (en) 2003-04-08 2011-12-20 Spiration, Inc. Bronchoscopic lung volume reduction method
US8136230B2 (en) 2007-10-12 2012-03-20 Spiration, Inc. Valve loader method, system, and apparatus
US8157760B2 (en) 2007-07-18 2012-04-17 Silk Road Medical, Inc. Methods and systems for establishing retrograde carotid arterial blood flow
US8298244B2 (en) 2006-10-26 2012-10-30 Tyco Healtcare Group Lp Intracorporeal grasping device
US8454708B2 (en) 2006-03-31 2013-06-04 Spiration, Inc. Articulable anchor
US8545432B2 (en) 2009-06-03 2013-10-01 Silk Road Medical, Inc. System and methods for controlling retrograde carotid arterial blood flow
US8795241B2 (en) 2011-05-13 2014-08-05 Spiration, Inc. Deployment catheter
US20140257019A1 (en) * 2013-03-05 2014-09-11 Sunshine Heart Company Pty, Ltd. Methods, Systems, and Devices Relating to a Fail-Safe Pump for a Medical Device
US8845621B2 (en) 2010-10-19 2014-09-30 Distal Access, Llc Apparatus for rotating medical devices, systems including the apparatus, and associated methods
US8858490B2 (en) 2007-07-18 2014-10-14 Silk Road Medical, Inc. Systems and methods for treating a carotid artery
US8945039B2 (en) * 2008-12-19 2015-02-03 Cvdevices, Llc Devices, systems, and methods for organ retroperfusion
US8974527B2 (en) 2003-08-08 2015-03-10 Spiration, Inc. Bronchoscopic repair of air leaks in a lung
US8974484B2 (en) 2001-09-11 2015-03-10 Spiration, Inc. Removable lung reduction devices, systems, and methods
US8979793B2 (en) 2002-01-24 2015-03-17 Lawrence Hofmann Methods and devices for percutaneous and surgical interventions
US9107691B2 (en) * 2010-10-19 2015-08-18 Distal Access, Llc Apparatus for rotating medical devices, systems including the apparatus, and associated methods
US9504781B2 (en) 2008-12-19 2016-11-29 Cvdevices, Llc Peripheral arterialization devices and methods of using the same
US9555176B2 (en) 2002-11-15 2017-01-31 Sunshine Heart Company Pty, Ltd. Implantable device utilizing arterial deformation
US9561375B2 (en) 2003-10-31 2017-02-07 Sunshine Heart Company Pty, Ltd. Synchronization control system
US9669191B2 (en) 2008-02-05 2017-06-06 Silk Road Medical, Inc. Interventional catheter system and methods
US9724214B2 (en) 2008-12-19 2017-08-08 Cvdevices, Llc Retroperfusion systems, devices, and methods
US10363354B2 (en) 2013-07-31 2019-07-30 Cvdevices, Llc Unitary body systems and devices and methods to use the same for retroperfusion
US11000307B2 (en) 2010-10-19 2021-05-11 Minerva Surgical Inc. Apparatus for rotating medical devices, systems including the apparatus, and associated methods
US11045300B2 (en) 2008-12-19 2021-06-29 Cvdevices, Llc Systems, devices, and methods for organ retroperfusion along with regional mild hypothermia
US11141259B2 (en) 2017-11-02 2021-10-12 Silk Road Medical, Inc. Fenestrated sheath for embolic protection during transcarotid carotid artery revascularization
US11298525B2 (en) * 2018-07-19 2022-04-12 Abiomed, Inc. Systems and methods for reducing leaks from a catheter
US11446050B2 (en) 2014-04-28 2022-09-20 Minerva Surgical, Inc. Tissue resectors with cutting wires, hand operated tissue resecting systems and associated methods

Families Citing this family (108)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6402771B1 (en) 1999-12-23 2002-06-11 Guidant Endovascular Solutions Snare
US6575997B1 (en) 1999-12-23 2003-06-10 Endovascular Technologies, Inc. Embolic basket
US6660021B1 (en) 1999-12-23 2003-12-09 Advanced Cardiovascular Systems, Inc. Intravascular device and system
US6695813B1 (en) 1999-12-30 2004-02-24 Advanced Cardiovascular Systems, Inc. Embolic protection devices
US7918820B2 (en) 1999-12-30 2011-04-05 Advanced Cardiovascular Systems, Inc. Device for, and method of, blocking emboli in vessels such as blood arteries
US6964670B1 (en) 2000-07-13 2005-11-15 Advanced Cardiovascular Systems, Inc. Embolic protection guide wire
US6506203B1 (en) * 2000-12-19 2003-01-14 Advanced Cardiovascular Systems, Inc. Low profile sheathless embolic protection system
US7422579B2 (en) 2001-05-01 2008-09-09 St. Jude Medical Cardiology Divison, Inc. Emboli protection devices and related methods of use
US7374560B2 (en) * 2001-05-01 2008-05-20 St. Jude Medical, Cardiology Division, Inc. Emboli protection devices and related methods of use
US7604612B2 (en) * 2001-05-01 2009-10-20 St. Jude Medical, Cardiology Division, Inc. Emboli protection devices and related methods of use
US6599307B1 (en) 2001-06-29 2003-07-29 Advanced Cardiovascular Systems, Inc. Filter device for embolic protection systems
US7338510B2 (en) 2001-06-29 2008-03-04 Advanced Cardiovascular Systems, Inc. Variable thickness embolic filtering devices and method of manufacturing the same
US6638294B1 (en) 2001-08-30 2003-10-28 Advanced Cardiovascular Systems, Inc. Self furling umbrella frame for carotid filter
US6592606B2 (en) 2001-08-31 2003-07-15 Advanced Cardiovascular Systems, Inc. Hinged short cage for an embolic protection device
US8262689B2 (en) 2001-09-28 2012-09-11 Advanced Cardiovascular Systems, Inc. Embolic filtering devices
US7241304B2 (en) 2001-12-21 2007-07-10 Advanced Cardiovascular Systems, Inc. Flexible and conformable embolic filtering devices
US7331973B2 (en) 2002-09-30 2008-02-19 Avdanced Cardiovascular Systems, Inc. Guide wire with embolic filtering attachment
US7252675B2 (en) 2002-09-30 2007-08-07 Advanced Cardiovascular, Inc. Embolic filtering devices
US20040088000A1 (en) 2002-10-31 2004-05-06 Muller Paul F. Single-wire expandable cages for embolic filtering devices
US8591540B2 (en) 2003-02-27 2013-11-26 Abbott Cardiovascular Systems Inc. Embolic filtering devices
DE602004009335T2 (en) * 2003-10-24 2008-07-03 ev3 Endovascular, Inc., Plymouth CLOSING SYSTEM FOR OPEN FORMS OVAL
US7892251B1 (en) 2003-11-12 2011-02-22 Advanced Cardiovascular Systems, Inc. Component for delivering and locking a medical device to a guide wire
US20050187568A1 (en) * 2004-02-20 2005-08-25 Klenk Alan R. Devices and methods for closing a patent foramen ovale with a coil-shaped closure device
US7678129B1 (en) 2004-03-19 2010-03-16 Advanced Cardiovascular Systems, Inc. Locking component for an embolic filter assembly
WO2005094283A2 (en) 2004-03-25 2005-10-13 Hauser David L Vascular filter device
US9320831B2 (en) * 2005-03-04 2016-04-26 W. L. Gore & Associates, Inc. Polymer shrink tubes and novel uses therefor
US9259305B2 (en) 2005-03-31 2016-02-16 Abbott Cardiovascular Systems Inc. Guide wire locking mechanism for rapid exchange and other catheter systems
US7955344B2 (en) * 2005-04-01 2011-06-07 Nexgen Medical Systems, Inc. Thrombus removal system and process
US7955345B2 (en) * 2005-04-01 2011-06-07 Nexgen Medical Systems, Inc. Thrombus removal system and process
US8221348B2 (en) * 2005-07-07 2012-07-17 St. Jude Medical, Cardiology Division, Inc. Embolic protection device and methods of use
US20070232905A1 (en) * 2006-04-04 2007-10-04 Francis Tom J Unconstrained Balloon Sizer
WO2008049088A2 (en) 2006-10-21 2008-04-24 Rollins Aaron M D Guidewire manipulation device
US8152786B2 (en) * 2006-11-07 2012-04-10 Osprey Medical, Inc. Collection catheter and kit
US20080132748A1 (en) * 2006-12-01 2008-06-05 Medical Value Partners, Llc Method for Deployment of a Medical Device
US8430837B2 (en) 2007-02-05 2013-04-30 Boston Scientific Scimed, Inc. Thrombectomy apparatus and method
US8333783B2 (en) * 2007-02-16 2012-12-18 Reverse Medical Corporation Occlusion device and method of use
US8216209B2 (en) 2007-05-31 2012-07-10 Abbott Cardiovascular Systems Inc. Method and apparatus for delivering an agent to a kidney
US7867273B2 (en) 2007-06-27 2011-01-11 Abbott Laboratories Endoprostheses for peripheral arteries and other body vessels
US20100228269A1 (en) * 2009-02-27 2010-09-09 Garrison Michi E Vessel closure clip device
EP2268351A4 (en) * 2008-04-08 2011-03-30 Reverse Medical Corp Occlusion device and method of use
US8574245B2 (en) * 2008-08-13 2013-11-05 Silk Road Medical, Inc. Suture delivery device
EP2323566A2 (en) 2008-08-13 2011-05-25 Silk Road Medical, Inc. Suture delivery device
US8758364B2 (en) 2008-08-29 2014-06-24 Rapid Medical Ltd. Device and method for clot engagement and capture
US9034008B2 (en) 2008-08-29 2015-05-19 Rapid Medical Ltd. Device and method involving stabilization during clot removal
US8864792B2 (en) 2008-08-29 2014-10-21 Rapid Medical, Ltd. Device and method for clot engagement
US9005237B2 (en) 2008-08-29 2015-04-14 Rapid Medical Ltd. Device and method for clot capture
US20110202088A1 (en) * 2008-10-24 2011-08-18 Rapid Medical Ltd. Embolectomy Device With Optional Vibrator
US20110152920A1 (en) * 2008-12-02 2011-06-23 Rapid Medical Ltd. Embolectomy device
US10226563B2 (en) 2008-12-23 2019-03-12 Silk Road Medical, Inc. Methods and systems for treatment of acute ischemic stroke
JP5818357B2 (en) * 2009-02-10 2015-11-18 ヴェサテック エルエルシー Method and apparatus for operating a surgical guidewire
WO2010093836A2 (en) * 2009-02-11 2010-08-19 Mark Mallaby Neurovascular microcatheter device, system and methods for use thereof
US8500775B2 (en) * 2009-12-02 2013-08-06 Surefire Medical, Inc. Protection device and method against embolization agent reflux
US9539081B2 (en) 2009-12-02 2017-01-10 Surefire Medical, Inc. Method of operating a microvalve protection device
US8696698B2 (en) * 2009-12-02 2014-04-15 Surefire Medical, Inc. Microvalve protection device and method of use for protection against embolization agent reflux
US9770319B2 (en) 2010-12-01 2017-09-26 Surefire Medical, Inc. Closed tip dynamic microvalve protection device
EP4101399A1 (en) 2011-08-05 2022-12-14 Route 92 Medical, Inc. System for treatment of acute ischemic stroke
US10779855B2 (en) 2011-08-05 2020-09-22 Route 92 Medical, Inc. Methods and systems for treatment of acute ischemic stroke
WO2013023126A2 (en) 2011-08-11 2013-02-14 Osprey Medical Inc. Systems and methods for limb treatment
US9089668B2 (en) 2011-09-28 2015-07-28 Surefire Medical, Inc. Flow directional infusion device
CN102350012B (en) * 2011-10-29 2014-05-28 北京梅德厚普科技有限公司 Stock solution filtration and exhaust unit and hematoma remover based on same
US9089341B2 (en) 2012-02-28 2015-07-28 Surefire Medical, Inc. Renal nerve neuromodulation device
US10342699B2 (en) 2012-08-03 2019-07-09 J.D. Franco & Co., Llc Systems and methods for treating eye diseases
WO2017156333A1 (en) 2016-03-09 2017-09-14 J.D. Franco & Co. Systems and methods for treating eye diseases using retrograde blood flow
US10159479B2 (en) 2012-08-09 2018-12-25 Silk Road Medical, Inc. Suture delivery device
US8784434B2 (en) 2012-11-20 2014-07-22 Inceptus Medical, Inc. Methods and apparatus for treating embolism
WO2015065910A2 (en) * 2013-10-30 2015-05-07 The Regents Of The University Of Michigan System and method to limit cerebral ischemia
US9265512B2 (en) 2013-12-23 2016-02-23 Silk Road Medical, Inc. Transcarotid neurovascular catheter
US9241699B1 (en) 2014-09-04 2016-01-26 Silk Road Medical, Inc. Methods and devices for transcarotid access
US9968740B2 (en) 2014-03-25 2018-05-15 Surefire Medical, Inc. Closed tip dynamic microvalve protection device
US9889031B1 (en) 2014-03-25 2018-02-13 Surefire Medical, Inc. Method of gastric artery embolization
US10182801B2 (en) 2014-05-16 2019-01-22 Silk Road Medical, Inc. Vessel access and closure assist system and method
US11027104B2 (en) 2014-09-04 2021-06-08 Silk Road Medical, Inc. Methods and devices for transcarotid access
EP3240507A4 (en) 2014-12-29 2018-12-05 Ocudyne LLC Apparatus and method for treating eye diseases
US11065019B1 (en) 2015-02-04 2021-07-20 Route 92 Medical, Inc. Aspiration catheter systems and methods of use
DE202016009165U1 (en) 2015-02-04 2023-04-26 Route 92 Medical, Inc. Rapid Aspiration Thrombectomy System
US20160287839A1 (en) 2015-03-31 2016-10-06 Surefire Medical, Inc. Apparatus and Method for Infusing an Immunotherapy Agent to a Solid Tumor for Treatment
CN107921243B (en) 2015-08-12 2021-03-09 维萨泰克有限公司 Systems and methods for operating elongate medical devices
US10561440B2 (en) 2015-09-03 2020-02-18 Vesatek, Llc Systems and methods for manipulating medical devices
AU2016341439B2 (en) 2015-10-23 2021-07-08 Inari Medical, Inc. Intravascular treatment of vascular occlusion and associated devices, systems, and methods
US10226263B2 (en) 2015-12-23 2019-03-12 Incuvate, Llc Aspiration monitoring system and method
US10123786B2 (en) 2016-09-16 2018-11-13 Krishna Rocha-Singh, M.D. Bone marrow harvesting device
US11400263B1 (en) 2016-09-19 2022-08-02 Trisalus Life Sciences, Inc. System and method for selective pressure-controlled therapeutic delivery
US10780250B1 (en) 2016-09-19 2020-09-22 Surefire Medical, Inc. System and method for selective pressure-controlled therapeutic delivery
CA3037713A1 (en) 2016-09-24 2018-03-29 J.D. Franco & Co., Llc Systems and methods for single puncture percutaneous reverse blood flow
WO2018080590A1 (en) 2016-10-24 2018-05-03 Inari Medical Devices and methods for treating vascular occlusion
AU2017370691A1 (en) 2016-12-08 2019-07-04 J.D. Franco & Co., Llc Methods and devices for treating an eye using a filter
WO2018140371A1 (en) 2017-01-25 2018-08-02 Rmvidlund Llc Blood vessel access and closure devices and related methods of use
US10588636B2 (en) 2017-03-20 2020-03-17 Surefire Medical, Inc. Dynamic reconfigurable microvalve protection device
US10898212B2 (en) 2017-05-07 2021-01-26 J.D. Franco & Co., Llc Devices and methods for treating an artery
US11000682B2 (en) 2017-09-06 2021-05-11 Inari Medical, Inc. Hemostasis valves and methods of use
US10779929B2 (en) 2017-10-06 2020-09-22 J.D. Franco & Co., Llc Treating eye diseases by deploying a stent
US10172634B1 (en) 2017-10-16 2019-01-08 Michael Bruce Horowitz Catheter based retrieval device with proximal body having axial freedom of movement
US20220104839A1 (en) 2017-10-16 2022-04-07 Retriever Medical, Inc. Clot Removal Methods and Devices with Multiple Independently Controllable Elements
US20220104840A1 (en) 2017-10-16 2022-04-07 Retriever Medical, Inc. Clot Removal Methods and Devices with Multiple Independently Controllable Elements
US10398880B2 (en) 2017-11-02 2019-09-03 J.D. Franco & Co., Llc Medical systems, devices, and related methods
US10758254B2 (en) 2017-12-15 2020-09-01 J.D. Franco & Co., Llc Medical systems, devices, and related methods
US11154314B2 (en) 2018-01-26 2021-10-26 Inari Medical, Inc. Single insertion delivery system for treating embolism and associated systems and methods
US11478249B2 (en) * 2018-02-23 2022-10-25 J.D. Franco & Co., Llc Ophthalmic artery therapy under reverse flow
AU2019269606A1 (en) 2018-05-17 2020-12-03 Route 92 Medical, Inc. Aspiration catheter systems and methods of use
US11678905B2 (en) 2018-07-19 2023-06-20 Walk Vascular, Llc Systems and methods for removal of blood and thrombotic material
US11850398B2 (en) 2018-08-01 2023-12-26 Trisalus Life Sciences, Inc. Systems and methods for pressure-facilitated therapeutic agent delivery
EP3836855A4 (en) 2018-08-13 2022-08-10 Inari Medical, Inc. System for treating embolism and associated devices and methods
US11338117B2 (en) 2018-10-08 2022-05-24 Trisalus Life Sciences, Inc. Implantable dual pathway therapeutic agent delivery port
US10668258B1 (en) 2018-12-31 2020-06-02 J.D. Franco & Co., Llc Intravascular devices, systems, and methods to address eye disorders
US11185334B2 (en) 2019-03-28 2021-11-30 DePuy Synthes Products, Inc. Single lumen reduced profile occlusion balloon catheter
EP4044938A4 (en) 2019-10-16 2023-11-15 Inari Medical, Inc. Systems, devices, and methods for treating vascular occlusions
US11090466B1 (en) * 2020-11-30 2021-08-17 TICI 3 Therapeutics, Inc. Catheter systems and devices for acute ischemic stroke thrombectomy
US11697003B2 (en) 2020-11-30 2023-07-11 TICI 3 Therapeutics, Inc. Vasculature navigation systems and methods

Citations (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3991767A (en) * 1973-11-02 1976-11-16 Cutter Laboratories, Inc. Tubular unit with vessel engaging cuff structure
US4273128A (en) * 1980-01-14 1981-06-16 Lary Banning G Coronary cutting and dilating instrument
US4575371A (en) * 1981-04-16 1986-03-11 Percy Nordqvist Urinary catheter
US4610656A (en) * 1984-08-21 1986-09-09 Mehealus Partnership Fully portable semi-automatic mechanical heart-lung substitution system and method
US4646736A (en) * 1984-09-10 1987-03-03 E. R. Squibb & Sons, Inc. Transluminal thrombectomy apparatus
US4706671A (en) * 1985-05-02 1987-11-17 Weinrib Harry P Catheter with coiled tip
US4911163A (en) * 1986-06-12 1990-03-27 Ernesto Fina Two ballooned catheter device for diagnostic and operative use
US4921478A (en) * 1988-02-23 1990-05-01 C. R. Bard, Inc. Cerebral balloon angioplasty system
US4968307A (en) * 1989-01-09 1990-11-06 Advanced Cardiovascular Systems, Inc. Catheter for uniform distribution of therapeutic fluids
US4994069A (en) * 1988-11-02 1991-02-19 Target Therapeutics Vaso-occlusion coil and method
US5011469A (en) * 1988-08-29 1991-04-30 Shiley, Inc. Peripheral cardiopulmonary bypass and coronary reperfusion system
US5011488A (en) * 1988-12-07 1991-04-30 Robert Ginsburg Thrombus extraction system
US5021045A (en) * 1988-04-28 1991-06-04 Research Medical, Inc. Retrograde venous cardioplegia catheters and methods of use and manufacture
US5185564A (en) * 1991-11-12 1993-02-09 Miller Michael C Battery discharge apparatus
US5425723A (en) * 1993-12-30 1995-06-20 Boston Scientific Corporation Infusion catheter with uniform distribution of fluids
US5643228A (en) * 1995-11-13 1997-07-01 Uresil Corporation Catheter
US5713853A (en) * 1995-06-07 1998-02-03 Interventional Innovations Corporation Methods for treating thrombosis
US5776100A (en) * 1995-09-27 1998-07-07 Interventional Innovations Corporation Nickel titanium guide wires for occlusion and drug delivery
US5782797A (en) * 1996-06-06 1998-07-21 Scimed Life Systems, Inc. Therapeutic infusion device
US5794629A (en) * 1996-11-27 1998-08-18 The Regents Of The University Of California Method for treating ischemic brain stroke
US5833650A (en) * 1995-06-05 1998-11-10 Percusurge, Inc. Catheter apparatus and method for treating occluded vessels
US5895398A (en) * 1996-02-02 1999-04-20 The Regents Of The University Of California Method of using a clot capture coil
US5908407A (en) * 1997-07-25 1999-06-01 Neuroperfusion, Inc. Retroperfusion catheter apparatus and method
US5910154A (en) * 1997-05-08 1999-06-08 Embol-X, Inc. Percutaneous catheter and guidewire having filter and medical device deployment
US5919163A (en) * 1997-07-14 1999-07-06 Delcath Systems, Inc. Catheter with slidable balloon
US5941869A (en) * 1997-02-12 1999-08-24 Prolifix Medical, Inc. Apparatus and method for controlled removal of stenotic material from stents
US5941896A (en) * 1997-09-08 1999-08-24 Montefiore Hospital And Medical Center Filter and method for trapping emboli during endovascular procedures
US5954737A (en) * 1997-12-19 1999-09-21 Neurovasx, Inc. Thrombus macerator catheter
US5972019A (en) * 1996-07-25 1999-10-26 Target Therapeutics, Inc. Mechanical clot treatment device
US6017493A (en) * 1997-09-26 2000-01-25 Baxter International Inc. Vacuum-assisted venous drainage reservoir for CPB systems
US6022336A (en) * 1996-05-20 2000-02-08 Percusurge, Inc. Catheter system for emboli containment
US6044845A (en) * 1998-02-03 2000-04-04 Salient Interventional Systems, Inc. Methods and systems for treating ischemia
US6059745A (en) * 1997-05-20 2000-05-09 Gelbfish; Gary A. Thrombectomy device and associated method
US6066149A (en) * 1997-09-30 2000-05-23 Target Therapeutics, Inc. Mechanical clot treatment device with distal filter
US6066158A (en) * 1996-07-25 2000-05-23 Target Therapeutics, Inc. Mechanical clot encasing and removal wire
US6105582A (en) * 1998-07-28 2000-08-22 Pranevicius; Osvaldas Cerebral blood outflow maintenance during intracranial hypertension
US6110139A (en) * 1997-10-21 2000-08-29 Loubser; Paul Gerhard Retrograde perfusion monitoring and control system
US6135991A (en) * 1997-03-06 2000-10-24 Percusurge, Inc. Aspiration method
US6146370A (en) * 1999-04-07 2000-11-14 Coaxia, Inc. Devices and methods for preventing distal embolization from the internal carotid artery using flow reversal by partial occlusion of the external carotid artery
US6152946A (en) * 1998-03-05 2000-11-28 Scimed Life Systems, Inc. Distal protection device and method
US6156046A (en) * 1997-11-07 2000-12-05 Prolifix Medical, Inc. Methods and systems for treating obstructions in a body lumen
US6161547A (en) * 1999-01-15 2000-12-19 Coaxia, Inc. Medical device for flow augmentation in patients with occlusive cerebrovascular disease and methods of use
US6165199A (en) * 1999-01-12 2000-12-26 Coaxia, Inc. Medical device for removing thromboembolic material from cerebral arteries and methods of use
US6203561B1 (en) * 1999-07-30 2001-03-20 Incept Llc Integrated vascular device having thrombectomy element and vascular filter and methods of use
US6206868B1 (en) * 1998-03-13 2001-03-27 Arteria Medical Science, Inc. Protective device and method against embolization during treatment of carotid artery disease
US6221042B1 (en) * 1999-09-17 2001-04-24 Scimed Life Systems, Inc. Balloon with reversed cones
US6231551B1 (en) * 1999-03-01 2001-05-15 Coaxia, Inc. Partial aortic occlusion devices and methods for cerebral perfusion augmentation
US6241699B1 (en) * 1998-07-22 2001-06-05 Chase Medical, Inc. Catheter system and method for posterior epicardial revascularization and intracardiac surgery on a beating heart
US6264672B1 (en) * 1999-10-25 2001-07-24 Biopsy Sciences, Llc Emboli capturing device
US6348056B1 (en) * 1999-08-06 2002-02-19 Scimed Life Systems, Inc. Medical retrieval device with releasable retrieval basket
US6361545B1 (en) * 1997-09-26 2002-03-26 Cardeon Corporation Perfusion filter catheter
US6383172B1 (en) * 1999-04-02 2002-05-07 Coaxia, Inc. Retrograde venous perfusion with isolation of cerebral circulation
US6413235B1 (en) * 1998-03-13 2002-07-02 Arteria Medical Science, Inc. Protective device against embolization in carotid angioplasty
US6419686B1 (en) * 1997-08-05 2002-07-16 Pearsalls Limited Occlusion device
US6423032B2 (en) * 1998-03-13 2002-07-23 Arteria Medical Science, Inc. Apparatus and methods for reducing embolization during treatment of carotid artery disease
US6435189B1 (en) * 1998-02-03 2002-08-20 Salient Interventional Systems, Inc. Methods and systems for treating ischemia
US6454775B1 (en) * 1999-12-06 2002-09-24 Bacchus Vascular Inc. Systems and methods for clot disruption and retrieval
US6458139B1 (en) * 1999-06-21 2002-10-01 Endovascular Technologies, Inc. Filter/emboli extractor for use in variable sized blood vessels
US6468291B2 (en) * 1999-07-16 2002-10-22 Baff Llc Emboli filtration system having integral strut arrangement and methods of use
US6485502B2 (en) * 2000-03-10 2002-11-26 T. Anthony Don Michael Vascular embolism prevention device employing filters
US6511492B1 (en) * 1998-05-01 2003-01-28 Microvention, Inc. Embolectomy catheters and methods for treating stroke and other small vessel thromboembolic disorders
US6533770B1 (en) * 1998-01-21 2003-03-18 Heartport, Inc. Cannula and method of manufacture and use
US6533800B1 (en) * 2001-07-25 2003-03-18 Coaxia, Inc. Devices and methods for preventing distal embolization using flow reversal in arteries having collateral blood flow
US6540712B1 (en) * 1998-03-13 2003-04-01 Arteria Medical Science, Inc. Methods and low profile apparatus for reducing embolization during treatment of carotid artery disease
US6555057B1 (en) * 1998-02-25 2003-04-29 Coaxia, Inc. Intravascular methods and apparatus for isolation and selective cooling of the cerebral vasculature during surgical procedures
US6595980B1 (en) * 2001-02-23 2003-07-22 Coaxia, Inc. Devices and methods for preventing distal embolization using flow reversal by occlusion of the brachiocephalic artery
US6595963B1 (en) * 2000-09-07 2003-07-22 Coaxia, Inc. Aortic shunt for selective cerebral perfusion in stroke and cardiac arrest
US6613046B1 (en) * 1999-11-22 2003-09-02 Scimed Life Systems, Inc. Loop structures for supporting diagnostic and therapeutic elements in contact with body tissue
US6632236B2 (en) * 1999-03-12 2003-10-14 Arteria Medical Science, Inc. Catheter having radially expandable main body
US6638293B1 (en) * 1996-02-02 2003-10-28 Transvascular, Inc. Methods and apparatus for blocking flow through blood vessels
US6645222B1 (en) * 1998-05-13 2003-11-11 Arteria Medical Science, Inc. Puncture resistant branch artery occlusion device and methods of use
US6673042B1 (en) * 1999-11-22 2004-01-06 Wilfred J. Samson Expandable venous cannula and method of use

Patent Citations (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3991767A (en) * 1973-11-02 1976-11-16 Cutter Laboratories, Inc. Tubular unit with vessel engaging cuff structure
US4273128A (en) * 1980-01-14 1981-06-16 Lary Banning G Coronary cutting and dilating instrument
US4575371A (en) * 1981-04-16 1986-03-11 Percy Nordqvist Urinary catheter
US4610656A (en) * 1984-08-21 1986-09-09 Mehealus Partnership Fully portable semi-automatic mechanical heart-lung substitution system and method
US4646736A (en) * 1984-09-10 1987-03-03 E. R. Squibb & Sons, Inc. Transluminal thrombectomy apparatus
US4706671A (en) * 1985-05-02 1987-11-17 Weinrib Harry P Catheter with coiled tip
US4911163A (en) * 1986-06-12 1990-03-27 Ernesto Fina Two ballooned catheter device for diagnostic and operative use
US4921478A (en) * 1988-02-23 1990-05-01 C. R. Bard, Inc. Cerebral balloon angioplasty system
US5021045A (en) * 1988-04-28 1991-06-04 Research Medical, Inc. Retrograde venous cardioplegia catheters and methods of use and manufacture
US5011469A (en) * 1988-08-29 1991-04-30 Shiley, Inc. Peripheral cardiopulmonary bypass and coronary reperfusion system
US4994069A (en) * 1988-11-02 1991-02-19 Target Therapeutics Vaso-occlusion coil and method
US5011488A (en) * 1988-12-07 1991-04-30 Robert Ginsburg Thrombus extraction system
US4968307A (en) * 1989-01-09 1990-11-06 Advanced Cardiovascular Systems, Inc. Catheter for uniform distribution of therapeutic fluids
US5185564A (en) * 1991-11-12 1993-02-09 Miller Michael C Battery discharge apparatus
US5425723A (en) * 1993-12-30 1995-06-20 Boston Scientific Corporation Infusion catheter with uniform distribution of fluids
US5833650A (en) * 1995-06-05 1998-11-10 Percusurge, Inc. Catheter apparatus and method for treating occluded vessels
US5713853A (en) * 1995-06-07 1998-02-03 Interventional Innovations Corporation Methods for treating thrombosis
US5776100A (en) * 1995-09-27 1998-07-07 Interventional Innovations Corporation Nickel titanium guide wires for occlusion and drug delivery
US5643228A (en) * 1995-11-13 1997-07-01 Uresil Corporation Catheter
US5895398A (en) * 1996-02-02 1999-04-20 The Regents Of The University Of California Method of using a clot capture coil
US6638293B1 (en) * 1996-02-02 2003-10-28 Transvascular, Inc. Methods and apparatus for blocking flow through blood vessels
US6436112B2 (en) * 1996-02-02 2002-08-20 The Regents Of The University Of California Method of using a clot capture coil
US6022336A (en) * 1996-05-20 2000-02-08 Percusurge, Inc. Catheter system for emboli containment
US5782797A (en) * 1996-06-06 1998-07-21 Scimed Life Systems, Inc. Therapeutic infusion device
US5972019A (en) * 1996-07-25 1999-10-26 Target Therapeutics, Inc. Mechanical clot treatment device
US6066158A (en) * 1996-07-25 2000-05-23 Target Therapeutics, Inc. Mechanical clot encasing and removal wire
US5794629A (en) * 1996-11-27 1998-08-18 The Regents Of The University Of California Method for treating ischemic brain stroke
US5941869A (en) * 1997-02-12 1999-08-24 Prolifix Medical, Inc. Apparatus and method for controlled removal of stenotic material from stents
US6135991A (en) * 1997-03-06 2000-10-24 Percusurge, Inc. Aspiration method
US5910154A (en) * 1997-05-08 1999-06-08 Embol-X, Inc. Percutaneous catheter and guidewire having filter and medical device deployment
US6059745A (en) * 1997-05-20 2000-05-09 Gelbfish; Gary A. Thrombectomy device and associated method
US5919163A (en) * 1997-07-14 1999-07-06 Delcath Systems, Inc. Catheter with slidable balloon
US5908407A (en) * 1997-07-25 1999-06-01 Neuroperfusion, Inc. Retroperfusion catheter apparatus and method
US6419686B1 (en) * 1997-08-05 2002-07-16 Pearsalls Limited Occlusion device
US5941896A (en) * 1997-09-08 1999-08-24 Montefiore Hospital And Medical Center Filter and method for trapping emboli during endovascular procedures
US6361545B1 (en) * 1997-09-26 2002-03-26 Cardeon Corporation Perfusion filter catheter
US6017493A (en) * 1997-09-26 2000-01-25 Baxter International Inc. Vacuum-assisted venous drainage reservoir for CPB systems
US6066149A (en) * 1997-09-30 2000-05-23 Target Therapeutics, Inc. Mechanical clot treatment device with distal filter
US6110139A (en) * 1997-10-21 2000-08-29 Loubser; Paul Gerhard Retrograde perfusion monitoring and control system
US6156046A (en) * 1997-11-07 2000-12-05 Prolifix Medical, Inc. Methods and systems for treating obstructions in a body lumen
US5954737A (en) * 1997-12-19 1999-09-21 Neurovasx, Inc. Thrombus macerator catheter
US6533770B1 (en) * 1998-01-21 2003-03-18 Heartport, Inc. Cannula and method of manufacture and use
US6435189B1 (en) * 1998-02-03 2002-08-20 Salient Interventional Systems, Inc. Methods and systems for treating ischemia
US6044845A (en) * 1998-02-03 2000-04-04 Salient Interventional Systems, Inc. Methods and systems for treating ischemia
US6555057B1 (en) * 1998-02-25 2003-04-29 Coaxia, Inc. Intravascular methods and apparatus for isolation and selective cooling of the cerebral vasculature during surgical procedures
US6152946A (en) * 1998-03-05 2000-11-28 Scimed Life Systems, Inc. Distal protection device and method
US6540712B1 (en) * 1998-03-13 2003-04-01 Arteria Medical Science, Inc. Methods and low profile apparatus for reducing embolization during treatment of carotid artery disease
US6206868B1 (en) * 1998-03-13 2001-03-27 Arteria Medical Science, Inc. Protective device and method against embolization during treatment of carotid artery disease
US6423032B2 (en) * 1998-03-13 2002-07-23 Arteria Medical Science, Inc. Apparatus and methods for reducing embolization during treatment of carotid artery disease
US6413235B1 (en) * 1998-03-13 2002-07-02 Arteria Medical Science, Inc. Protective device against embolization in carotid angioplasty
US6511492B1 (en) * 1998-05-01 2003-01-28 Microvention, Inc. Embolectomy catheters and methods for treating stroke and other small vessel thromboembolic disorders
US6645222B1 (en) * 1998-05-13 2003-11-11 Arteria Medical Science, Inc. Puncture resistant branch artery occlusion device and methods of use
US6241699B1 (en) * 1998-07-22 2001-06-05 Chase Medical, Inc. Catheter system and method for posterior epicardial revascularization and intracardiac surgery on a beating heart
US6105582A (en) * 1998-07-28 2000-08-22 Pranevicius; Osvaldas Cerebral blood outflow maintenance during intracranial hypertension
US6165199A (en) * 1999-01-12 2000-12-26 Coaxia, Inc. Medical device for removing thromboembolic material from cerebral arteries and methods of use
US6161547A (en) * 1999-01-15 2000-12-19 Coaxia, Inc. Medical device for flow augmentation in patients with occlusive cerebrovascular disease and methods of use
US6231551B1 (en) * 1999-03-01 2001-05-15 Coaxia, Inc. Partial aortic occlusion devices and methods for cerebral perfusion augmentation
US6632236B2 (en) * 1999-03-12 2003-10-14 Arteria Medical Science, Inc. Catheter having radially expandable main body
US6383172B1 (en) * 1999-04-02 2002-05-07 Coaxia, Inc. Retrograde venous perfusion with isolation of cerebral circulation
US6146370A (en) * 1999-04-07 2000-11-14 Coaxia, Inc. Devices and methods for preventing distal embolization from the internal carotid artery using flow reversal by partial occlusion of the external carotid artery
US6458139B1 (en) * 1999-06-21 2002-10-01 Endovascular Technologies, Inc. Filter/emboli extractor for use in variable sized blood vessels
US6468291B2 (en) * 1999-07-16 2002-10-22 Baff Llc Emboli filtration system having integral strut arrangement and methods of use
US6203561B1 (en) * 1999-07-30 2001-03-20 Incept Llc Integrated vascular device having thrombectomy element and vascular filter and methods of use
US6348056B1 (en) * 1999-08-06 2002-02-19 Scimed Life Systems, Inc. Medical retrieval device with releasable retrieval basket
US6221042B1 (en) * 1999-09-17 2001-04-24 Scimed Life Systems, Inc. Balloon with reversed cones
US6264672B1 (en) * 1999-10-25 2001-07-24 Biopsy Sciences, Llc Emboli capturing device
US6613046B1 (en) * 1999-11-22 2003-09-02 Scimed Life Systems, Inc. Loop structures for supporting diagnostic and therapeutic elements in contact with body tissue
US6673042B1 (en) * 1999-11-22 2004-01-06 Wilfred J. Samson Expandable venous cannula and method of use
US6454775B1 (en) * 1999-12-06 2002-09-24 Bacchus Vascular Inc. Systems and methods for clot disruption and retrieval
US6485502B2 (en) * 2000-03-10 2002-11-26 T. Anthony Don Michael Vascular embolism prevention device employing filters
US6595963B1 (en) * 2000-09-07 2003-07-22 Coaxia, Inc. Aortic shunt for selective cerebral perfusion in stroke and cardiac arrest
US6595980B1 (en) * 2001-02-23 2003-07-22 Coaxia, Inc. Devices and methods for preventing distal embolization using flow reversal by occlusion of the brachiocephalic artery
US6533800B1 (en) * 2001-07-25 2003-03-18 Coaxia, Inc. Devices and methods for preventing distal embolization using flow reversal in arteries having collateral blood flow

Cited By (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8974484B2 (en) 2001-09-11 2015-03-10 Spiration, Inc. Removable lung reduction devices, systems, and methods
US7896887B2 (en) 2001-10-25 2011-03-01 Spiration, Inc. Apparatus and method for deployment of a bronchial obstruction device
US20030183235A1 (en) * 2001-10-25 2003-10-02 Spiration, Inc. Bronchial obstruction device deployment system and method
US8986336B2 (en) 2001-10-25 2015-03-24 Spiration, Inc. Apparatus and method for deployment of a bronchial obstruction device
US8979793B2 (en) 2002-01-24 2015-03-17 Lawrence Hofmann Methods and devices for percutaneous and surgical interventions
US7942931B2 (en) 2002-02-21 2011-05-17 Spiration, Inc. Device and method for intra-bronchial provision of a therapeutic agent
US8926647B2 (en) 2002-03-20 2015-01-06 Spiration, Inc. Removable anchored lung volume reduction devices and methods
US8177805B2 (en) 2002-03-20 2012-05-15 Spiration, Inc. Removable anchored lung volume reduction devices and methods
US8021385B2 (en) 2002-03-20 2011-09-20 Spiration, Inc. Removable anchored lung volume reduction devices and methods
US7875048B2 (en) 2002-05-17 2011-01-25 Spiration, Inc. One-way valve devices for anchored implantation in a lung
US7842061B2 (en) 2002-05-17 2010-11-30 Spiration, Inc. Methods of achieving lung volume reduction with removable anchored devices
US8956319B2 (en) 2002-05-17 2015-02-17 Spiration, Inc. One-way valve devices for anchored implantation in a lung
US8257381B2 (en) 2002-05-17 2012-09-04 Spiration, Inc. One-way valve devices for anchored implantation in a lung
US9555176B2 (en) 2002-11-15 2017-01-31 Sunshine Heart Company Pty, Ltd. Implantable device utilizing arterial deformation
US8079368B2 (en) 2003-04-08 2011-12-20 Spiration, Inc. Bronchoscopic lung volume reduction method
US8974527B2 (en) 2003-08-08 2015-03-10 Spiration, Inc. Bronchoscopic repair of air leaks in a lung
US9622752B2 (en) 2003-08-08 2017-04-18 Spiration, Inc. Bronchoscopic repair of air leaks in a lung
US9561375B2 (en) 2003-10-31 2017-02-07 Sunshine Heart Company Pty, Ltd. Synchronization control system
US8002728B2 (en) 2003-11-21 2011-08-23 Silk Road Medical, Inc. Method and apparatus for treating a carotid artery
US9526504B2 (en) 2003-11-21 2016-12-27 Silk Road Medical, Inc. Method and apparatus for treating a carotid artery
US8343089B2 (en) 2003-11-21 2013-01-01 Silk Road Medical, Inc. Method and apparatus for treating a carotid artery
US8414516B2 (en) 2003-11-21 2013-04-09 Silk Road Medical, Inc. Method and apparatus for treating a carotid artery
US8870805B2 (en) 2003-11-21 2014-10-28 Silk Road Medical, Inc. Method and apparatus for treating a carotid artery
US9662118B2 (en) 2003-11-21 2017-05-30 Silk Road Medical, Inc. Method and apparatus for treating a carotid artery
US11849954B2 (en) 2003-11-21 2023-12-26 Silk Road Medical, Inc. Method and apparatus for treating an arterial lesion
US10779835B2 (en) 2003-11-21 2020-09-22 Silk Road Medical, Inc. Method and apparatus for treating a carotid artery
US10722239B2 (en) 2003-11-21 2020-07-28 Silk Road Medical, Inc. Method and apparatus for treating an arterial lesion
US7998104B2 (en) 2003-11-21 2011-08-16 Silk Road Medical, Inc. Method and apparatus for treating a carotid artery
US11918226B2 (en) 2003-11-21 2024-03-05 Silk Road Medical, Inc. Method and apparatus for treating an arterial lesion
US10188399B2 (en) 2003-11-21 2019-01-29 Silk Road Medical, Inc. Method and apparatus for treating a carotid artery
US7491101B2 (en) * 2004-06-17 2009-02-17 Illinois Tool Works Inc. Self-locking wire terminal and shape memory wire termination system
US20050282444A1 (en) * 2004-06-17 2005-12-22 Irish Kenneth G Self-locking wire terminal and shape memory wire termination system
US9198669B2 (en) 2006-03-31 2015-12-01 Spiration, Inc. Articulable anchor
US8647392B2 (en) 2006-03-31 2014-02-11 Spiration, Inc. Articulable anchor
US8454708B2 (en) 2006-03-31 2013-06-04 Spiration, Inc. Articulable anchor
US8298244B2 (en) 2006-10-26 2012-10-30 Tyco Healtcare Group Lp Intracorporeal grasping device
US10085864B2 (en) 2007-07-18 2018-10-02 Silk Road Medical, Inc. Systems and methods for treating a carotid artery
US10709832B2 (en) 2007-07-18 2020-07-14 Silk Road Medical, Inc. Methods and systems for establishing retrograde carotid arterial blood flow
US8858490B2 (en) 2007-07-18 2014-10-14 Silk Road Medical, Inc. Systems and methods for treating a carotid artery
US9011364B2 (en) 2007-07-18 2015-04-21 Silk Road Medical, Inc. Methods and systems for establishing retrograde carotid arterial blood flow
US8157760B2 (en) 2007-07-18 2012-04-17 Silk Road Medical, Inc. Methods and systems for establishing retrograde carotid arterial blood flow
US10426885B2 (en) 2007-07-18 2019-10-01 Silk Road Medical, Inc. Methods and systems for establishing retrograde carotid arterial blood flow
US9833555B2 (en) 2007-07-18 2017-12-05 Silk Road Medical, Inc. Methods and systems for establishing retrograde carotid arterial blood flow
US11364332B2 (en) 2007-07-18 2022-06-21 Silk Road Medical, Inc. Methods and systems for establishing retrograde carotid arterial blood flow
US9789242B2 (en) 2007-07-18 2017-10-17 Silk Road Medical, Inc. Methods and systems for establishing retrograde carotid arterial blood flow
US9259215B2 (en) 2007-07-18 2016-02-16 Silk Road Medical, Inc. Systems and methods for treating a carotid artery
US10485917B2 (en) 2007-07-18 2019-11-26 Silk Road Medical, Inc. Methods and systems for establishing retrograde carotid arterial blood flow
US10952882B2 (en) 2007-07-18 2021-03-23 Silk Road Medical, Inc. Systems and methods for treating a carotid artery
US10543307B2 (en) 2007-07-18 2020-01-28 Silk Road Medical, Inc. Methods and systems for establishing retrograde carotid arterial blood flow
US10286139B2 (en) 2007-07-18 2019-05-14 Silk Road Medical, Inc. Methods and systems for establishing retrograde carotid arterial blood flow
US8784355B2 (en) 2007-07-18 2014-07-22 Silk Road Medical, Inc. Methods and systems for establishing retrograde carotid arterial blood flow
US8740834B2 (en) 2007-07-18 2014-06-03 Silk Road Medical, Inc. Methods and systems for establishing retrograde carotid arterial blood flow
US9655755B2 (en) 2007-07-18 2017-05-23 Silk Road Medical, Inc. Systems and methods for treating a carotid artery
US8043301B2 (en) 2007-10-12 2011-10-25 Spiration, Inc. Valve loader method, system, and apparatus
US9326873B2 (en) 2007-10-12 2016-05-03 Spiration, Inc. Valve loader method, system, and apparatus
US8136230B2 (en) 2007-10-12 2012-03-20 Spiration, Inc. Valve loader method, system, and apparatus
US9669191B2 (en) 2008-02-05 2017-06-06 Silk Road Medical, Inc. Interventional catheter system and methods
US11364369B2 (en) 2008-02-05 2022-06-21 Silk Road Medical, Inc. Interventional catheter system and methods
US20090198172A1 (en) * 2008-02-05 2009-08-06 Garrison Michi E Interventional sheath with retention features
US10226598B2 (en) 2008-02-05 2019-03-12 Silk Road Medical, Inc. Interventional catheter system and methods
US9242068B2 (en) 2008-07-17 2016-01-26 Covidien Lp Spirally conformable infusion catheter
US20100016832A1 (en) * 2008-07-17 2010-01-21 Tyco Healthcare Group Lp Spirally conformable infusion catheter
US10736729B2 (en) 2008-12-19 2020-08-11 Cvdevices, Llc Peripheral arterialization devices and methods of using the same
US11045300B2 (en) 2008-12-19 2021-06-29 Cvdevices, Llc Systems, devices, and methods for organ retroperfusion along with regional mild hypothermia
US9724214B2 (en) 2008-12-19 2017-08-08 Cvdevices, Llc Retroperfusion systems, devices, and methods
US8945039B2 (en) * 2008-12-19 2015-02-03 Cvdevices, Llc Devices, systems, and methods for organ retroperfusion
US9504781B2 (en) 2008-12-19 2016-11-29 Cvdevices, Llc Peripheral arterialization devices and methods of using the same
US9138527B2 (en) 2009-06-03 2015-09-22 Silk Road Medical, Inc. System and methods for controlling retrograde carotid arterial blood flow
US8545432B2 (en) 2009-06-03 2013-10-01 Silk Road Medical, Inc. System and methods for controlling retrograde carotid arterial blood flow
US9931495B2 (en) 2010-02-23 2018-04-03 Covidien Lp Devices and methods for vascular recanalization
US10300256B2 (en) 2010-02-23 2019-05-28 Covidien Lp Devices and methods for vascular recanalization
US9211396B2 (en) 2010-02-23 2015-12-15 Covidien Lp Devices and methods for vascular recanalization
US20110213403A1 (en) * 2010-02-23 2011-09-01 Maria Aboytes Devices and methods for vascular recanalization
US8845621B2 (en) 2010-10-19 2014-09-30 Distal Access, Llc Apparatus for rotating medical devices, systems including the apparatus, and associated methods
US11000307B2 (en) 2010-10-19 2021-05-11 Minerva Surgical Inc. Apparatus for rotating medical devices, systems including the apparatus, and associated methods
US9107691B2 (en) * 2010-10-19 2015-08-18 Distal Access, Llc Apparatus for rotating medical devices, systems including the apparatus, and associated methods
US8795241B2 (en) 2011-05-13 2014-08-05 Spiration, Inc. Deployment catheter
US20140257019A1 (en) * 2013-03-05 2014-09-11 Sunshine Heart Company Pty, Ltd. Methods, Systems, and Devices Relating to a Fail-Safe Pump for a Medical Device
US10363354B2 (en) 2013-07-31 2019-07-30 Cvdevices, Llc Unitary body systems and devices and methods to use the same for retroperfusion
US11446050B2 (en) 2014-04-28 2022-09-20 Minerva Surgical, Inc. Tissue resectors with cutting wires, hand operated tissue resecting systems and associated methods
US11141259B2 (en) 2017-11-02 2021-10-12 Silk Road Medical, Inc. Fenestrated sheath for embolic protection during transcarotid carotid artery revascularization
US11864988B2 (en) 2017-11-02 2024-01-09 Silk Road Medical, Inc. Fenestrated sheath for embolic protection during transcarotid carotid artery revascularization
US11298525B2 (en) * 2018-07-19 2022-04-12 Abiomed, Inc. Systems and methods for reducing leaks from a catheter

Also Published As

Publication number Publication date
US6902540B2 (en) 2005-06-07
US20030040694A1 (en) 2003-02-27

Similar Documents

Publication Publication Date Title
US6902540B2 (en) Apparatus and methods for treating stroke and controlling cerebral flow characteristics
US7063714B2 (en) Apparatus and methods for treating stroke and controlling cerebral flow characteristics
CA2458148C (en) Apparatus and methods for treating stroke and controlling cerebral flow characteristics
US20030040762A1 (en) Apparatus and methods for treating stroke and controlling cerebral flow characteristics
US6929634B2 (en) Apparatus and methods for treating stroke and controlling cerebral flow characteristics
US11207095B2 (en) Devices and systems for thrombus treatment
CN107920827B (en) Axially elongated thrombus capture system
US6135991A (en) Aspiration method
JP2005523123A (en) Infusion catheter with atraumatic tip
WO2014204860A1 (en) Methods and systems for tretment of acute ischemic stroke
AU2013266995A1 (en) Apparatus and methods for treating stroke and controlling cerebral flow characteristics
AU2012209037B2 (en) Apparatus and methods for treating stroke and controlling cerebral flow characteristics
CN113856001A (en) Isolated stent implantation with distal balloon
JP2013017833A (en) Apparatus and method for treating stroke and controlling cerebral flow characteristics
AU2002336389A1 (en) Apparatus and methods for treating stroke and controlling cerebral flow characteristics

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION

AS Assignment

Owner name: W. L. GORE & ASSOCIATES, INC., DELAWARE

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:GORE ENTERPRISE HOLDINGS, INC.;REEL/FRAME:027906/0508

Effective date: 20120130